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Abstract  
Silicon has been shown to be an important trace element in bone formation and metabolism, 
and a decrease in silicon in the mammalian diet leads to abnormal bone formation. 
Consequently, silicon has been incorporated into many biomaterials to enhance bone 
generation around implants. Despite this, the mechanism of action has still not been 
elucidated and a therapeutic dosage has not been determined. 
In this thesis, the optimum concentration of orthosilicic acid (OSA) to enable cell survival and 
early mineralisation has been identified. It was noted that a dosage of 5µg/ml of OSA 
enhanced bone nodule formation. The presence of OSA increased the expression of early 
osteogenic markers such as osteopontin, osteocalcin and type 1 collagen. In addition, 
increasing OSA concentration resulted in the development of a collagen fibril network of 
increasing complexity, up to supraphysiological OSA concentrations when the fibril network 
became fragmented. It was hypothesised that this may assist with mineral deposition.  
A sustained delivery system was also developed using a combination of PLGA and calcium 
silicate. A sustained dose of orthosilicic acid ideal for cell survival was released from the 
PLGA micro-particles containing calcium silicate.  As well as providing a source of OSA, the 
presence of the alkaline degradation products of calcium silicate aided in the neutralisation of 
the acidic degradation products of PLGA, which might enhance cell viability in the local 
environment. In addition to influencing cell behaviour, the OSA was shown to have a strong 
interaction with alginate, modifying its properties and preventing degradation.  This finding is 
of importance as the molecules comprising alginate bear a structural resemblance to the 
glycosaminoglycans that are found in the majority of tissues. 
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1. Introduction 
Bone related diseases such as osteoporosis and rheumatoid arthritis have an immense impact 
on an individual’s health as well as the population at large, resulting in high financial costs to 
national economies (Harvey et al. 2010). With a global shift towards an aging population, 
there is a large increase associated with bone related diseases. Consequently this has led to a 
demand for biomaterial-based treatments in orthopaedics (Stevens 2008).  
A large volume of bone may be removed for the treatment of disease (Raisz 1999), genetic 
abnormalities (Rucci 2008) or trauma (Arcos & Vallet-Regí 2010).  Bone grafts are used to 
enhance the healing process as well as prevent fibrosis occurring within the defect (Palmer et 
al. 2009). Two million bone grafting procedures are undertaken annually, with most of them 
using the ‘gold standard’ autograph procedure (Walschot et al. 2012). Allografts (Lavernia et 
al. 2004) and xenografts (Navarro et al. 2008) are other biological bone grafts often used in 
treating bone defects. Although these bone grafting procedures have been shown to be 
successful in the augmentation of bone defects they still have major disadvantages, such as, 
immune rejection and disease transmission (Rupani et al. 2012).  This has stimulated research 
into the development of novel approaches to replace tissue bone grafting.  
Many synthetic materials such as polymers (Gunatillake & Adhikari 2003), metals (Matsuno 
et al. 2001), hydrogels (Hunt et al. 2010), glass (Hench 2009) and cement (Ohtsuki et al. 
2009) have been investigated as bone replacement materials. An ideal biomaterial for bone 
replacement should enhance the healing of the bone tissue and yet resorb without non-
cytotoxicity (Hing 2004), as well as performing a mechanical role by supporting the 
surrounding tissues. To date, however, autografts are still being used as the materials of 
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choice for bone replacements as they stimulate bone growth and healing, resulting in good 
clinical results (Jones 2013).  
Many ions have been detected in the body at trace levels and have been shown to elicit strong 
biological responses. For example, copper has been shown to promote blood vessel formation 
(Sen et al. 2002), zinc has been shown to enhance healing in fractured bone (Towler et al. 
2009) and silicon has been shown to play a key role in the calcification of young bone 
(Carlisle 1976). This has therefore led to an increase in investigations incorporating silicon 
into various biomaterials, with a number reaching the market as promising bone replacement 
materials. Xynos et al (2000) demonstrated the effect of silicon from a phosphosilicate glass 
(Bioglass
®
)
 
and showed the osseointegration of the material within the implanted site without 
the occurance of fibrosis (Xynos et al. 2000). Others have attempted to incorporate silicon 
into the hydroxyapatite lattice (Patel et al. 2002) and other calcium phosphate ceramics (Ni et 
al. 2008). These materials have been shown to have a significant effect on osteogenesis when 
compared to the non-modified ceramics. There is no complete consensus, however, as to how 
silicon functions to enhance mineralisation. Previously it has been reported by Reffit et al 
(2003) that the soluble form of silicon; orthosilicic acid enhances collagen 1 expression 
(Reffitt et al. 2003). At the same time little work has been done to determine the local release 
of orthosilicic acid from these biomaterials in vitro and in vivo. Therefore, the therapeutic 
dose of orthosilicic acid released from these materials, which will maximise hard tissue 
formation, has yet to be established. 
The work reported in this thesis systematically evaluated the effect of silicon in its soluble 
form, orthosilicic acid (OSA), on cell viability, collagen excretion and formation, as well as 
mineral deposition. By identifying the role of silicon and the therapeutic dosage of silicon a 
delivery system was developed to release a sustained dosage of orthosilicic acid over a period 
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of time.  Work has also been undertaken to determine how orthosilicic acid may interact with 
and modify the structures of a number of biomaterials, including alginate. 
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2. Literature review 
2.1 Bone Biology 
In the past, the skeleton has often had a reputation of being an inert and static material. 
However, given that bone tissue has the ability to repair itself and its capacity to rapidly 
mobilise mineral stores on metabolic demand it is in fact a ‘smart’ material (Sommerfeldt & 
Rubin 2001), and a dynamic biological system. Bone is a dense multi-phase composite made 
up of cells embedded in a matrix composed of organic and inorganic elements. Its structure 
usually differs widely, depending on age, site and history leading to its classifications by 
mechanical and functional characteristics (Hing 2004). Although bone’s primary role is to 
maintain the body’s structure it is also responsible for maintaining mineral homeostasis, and 
acts as a source of haematopoietic stem cells. Bone in its natural environment is involved in a 
continuous cycle of resorption and renewal, therefore always undergoing a chemical exchange 
and structural remodelling, due to internal hormonal regulation and external mechanical 
demands (Grosland 2001). The mineral storage however, can exceed the structural function 
resulting in the loss of the bone structure.   
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2.2 Bone structure  
Bone is a complex and dynamic living tissue that is continually reshaped and remodelled to 
provide dynamic mechanical support and facilitate for movement in vertebrates. It also acts as 
protection for internal organs against injury, for example the ribs protect all the organs in the 
thoracic cavity. Morphologically bone is divided into two types on the basis of porosity and 
the microstructure: 
Trabecular/ cancellous bone: make up only 20% of the skeleton – Trabecular bone is mainly 
made up of a loosely organised porous matrix of interconnecting columns and these spaces 
are filled with bone-marrow (Tuan et al. 2003). The mechanical properties of cancellous bone 
are mostly dependent upon porosity and architecture, both which vary due to the location and 
age of the bone. In addition, cancellous bone is often anisotropic due to the orientation of 
major trabeculae along the lines of principle stress (Kuo & Carter 1991).  
Cortical / compact bone; Cortical bone comprises of 80% of the mass of the skeleton. 
Compact bone is dense with a porosity ranging between 5% - 10%. It is primarily found in the 
diaphyses of long bones and forms the outer shell around the cancellous bone at the end of 
joints and vertebrae (Grosland 2001). Cortical bone is arranged in a series of concentric rings 
known as osteons, which surround the central Haversian canal, this consists of blood vessels 
which are laterally linked by Volkmann’s canals (Hogan 1992). Osteocytes surrounded by the 
osseous matrix are found in pores within the osteons and enable the exchange of nutrients, 
growth factors and factors responsible for maintaining mineral levels within the body (Figure 
1.1) (Hing 2005) 
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Figure 2.1: Sectioned human femoral head, showing the differences in bone structure (a). 
Structure of the cortical bone including Haversian canal and interconnecting Volksmann 
canal (b) (National Cancer Institute, 2012)  
Both cortical and cancellous bones are surrounded by fibrous connective tissue known as the 
periosteum (Figure 2.1b). The periosteum provides a blood supply and innervation on the 
bone surface, in addition it is the main store of osteoprogenitor cells and osteoblasts, and 
therefore plays a vital role in fracture repair (Rowe & Tracey 2005).  
Cortical bone is mainly known for its protection and load –bearing capabilities to bone while 
trabecular bone is responsible for metabolic functions of bone. Cortical bone appears in 
various shapes such as:  
1. Long bones: these have a greater length than width and consist of a shaft and a 
variable number of endings; their primary function is strength and examples include, 
femur, tibia, fibula, humerus, ulna and radius.   
 
Chapter 2 
 
7 
 
2. Flat bones: have a thin structure and provide considerable mechanical protection and 
large surfaces for muscle attachment, examples include cranial bones (that protect the 
brain), the sternum and ribs (protecting the organs in the thorax) and the scapulae, also 
known as, shoulder blades.  
Cancellous bone can be further classified into coarse and fine; coarse cancellous bone is 
characteristic of a healthy adult mammalian skeleton, while fine cancellous bone is often 
found in the foetal skeleton or early fracture callus.   
Bone also functions in mineral homeostasis and stores several vital minerals, especially 
calcium and phosphorous, which it can release into the bloodstream to maintain critical 
mineral balances. Furthermore bone can suffer from pathological conditions for example 
cancer, and can degrade as a result of age and disease, that is, osteoporosis. 
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2.2.1  Cell types in bone metabolism   
Various cell types are responsible for the continuous remodelling and resorption of bone 
tissue. These distinct lineages can be found within the bone: osteoblasts and osteocytes, these 
are responsible for mineral deposition and homeostasis respectively and osteoclasts are 
involved in bone resorption process.  
2.2.1.1 Osteoblasts  
Osteoblasts are mononucleated cells derived from multipotent mesenchymal stem cells. They 
can be differentiated into various mesenchymal lineages, such as fibroblasts, chondrocytes, 
myoblasts and adipocytes, depending on the activated transcription signalling pathways 
(Yamaguchi et al. 2000).  
Several specific transcription factors are responsible for the commitment of multipotent 
mesenchymal cells into the osteoblast cell lineage. Core binding factor α 1 (Cbfα-1) , also 
known as, Runx – 2, a transcription factor part of the runt domain gene family, plays a critical 
role in osteoblast differentiation. It is involved in the production of bone matrix proteins and it 
is able to up-regulate the expression of major bone matrix protein genes, such as type 1 
collagen, osteopontin, bone sialoproteins and osteocalcin (Fukuoka et al. 2007) leading to an 
increase in the number of immature osteoblasts from multipotent stem cells.  
Differentiated osteoblasts are responsible for bone formation process and in the mineralisation 
of the extracellular bone matrix. They play an important role in the modulation of bone 
remodelling as well as in the regulation of the metabolic activity of other bone cells via the 
receptor activator of nuclear factor κ – B ligand and osteoprotegrin (OPG). Inadequate 
osteoblastic function is responsible in the number of human bone related diseases such as 
osteoporosis and rheumatoid arthritis.  
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2.2.1.2 Osteocytes 
Osteocytes are fully differentiated, non-proliferating cells, and are localised in the mineralised 
bone matrix and in newly synthesised osteoids. They are derived from active osteoblasts, 
which become encased within the bone matrix during bone formation, after the completion of 
ECM synthesis and mineralisation, 10-20% of osteoblasts differentiate into osteocytes 
(Andreassen & Oxlund 2001). Several studies showed that osteocytes express specific 
markers for bone formation and phosphate homeostasis. Dentin matrix protein 1 (DMP1), 
matrix extracellular phosphoglycoprotein (MEPE) and sclerostin are gene markers that are 
involved in phosphate homeostasis. They are also key endocrine regulators for bone 
metabolism, and are sensitive to parathyroid hormone and calcitonin, and are therefore 
responsible for maintaining plasma calcium levels in the body (Matsuo & Irie 2008). 
Osteocytes secrete signalling molecules such as nitric oxide and prostaglandin E2 to initiate 
bone remodelling (Guo & Bonewald 2009). 
Osteocytes are also involved in the maintenance of the dynamic equilibrium between 
osteoblast and osteoclast cells, and therefore play a vital role in the bone remodelling and 
bone resorption processes.   
2.2.1.3 Osteoclasts 
Osteoclast cells are continuously ‘destroying’ the very organ that the body is trying to form 
(Phan et al. 2004). Osteoclasts are multinucleated cells, derived from haemopoetic cells lines 
of the monocyte/macrophage lineage (Rucci 2008). The differentiation of osteoclasts occurs 
with close contact to stromal cells and the interaction between monocyte precursors and 
osteoblasts shown in Figure 2.2. The production of two haematopoetic factors, from stromal 
cells, the TNF-related cytokine RANKL and the polypeptide growth factor CSF-1 assist in 
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promoting osteoclast genesis and for the activation of RANKL on the surface of 
haematopoetic precursor cells (Fox & Lovibond 2005).   
Osteoclasts lie in the Howship’s lacunae, small conical cavities within the bone matrix (Raisz 
1999). An actin ring creates a tight junction between the cell and the surface of the bone and 
the osteoclasts begin to form a polarised morphology. Proton pumps such as the ATPase ion 
pump in osteoclasts, pumps hydrogen ions against a high concentration gradient into the 
cavities acidifying (Equation 2-1) and dissolving the mineralised bone matrix into Ca
2+
, 
H3PO4, H2CO3 and H2O (Francis et al. 2002). 
H2O + CO2  HCO3
- 
+ H
+ 
Equation 2-1 
Additionally several hydrolytic enzymes including collagenase and cathepsin K are released 
in the lacuna via lysosomes to degrade the organic matrix (Matsuo & Irie 2008). This leads to 
debris of calcium salts and protease products which are endocytosed by the cell and form 
vesicles in the cytoplasm before excretion. Regulation of osteoclastic differentiation and 
activity is monitored by various hormones, such as parathyroid hormone (PTH), calcitonin 
and Interleukin 6 (IL-6) (Hadjidakis & Androulakis 2006).  
Imbalances between osteoblastic and osteclastic activity can result in various bone related 
diseases such as Paget’s disease occurs due to osteoclasts over activity and osteopetrosis due 
to insufficient osteoclast activity (Raisz 1999). 
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Figure 2.2: TEM image of osteoclast – osteoblast contact in 14 week old mouse tibial bone. 
Arrows show contact surface between osteoclasts (OC) and osteoblasts (OB). Scale bar 5µm 
(Matsuo & Irie 2008) 
2.2.2 Bone remodelling  
2.2.2.1 Bone formation and metabolism 
Bone formation is first observed when undifferentiated mesenchymal cells or pre-osteoblasts 
take on the appearance of osteoblasts which begin to secrete a specialised extracellular matrix. 
The matrix starts to mineralise and the pre- osteoblasts surrounded by the matrix are 
differentiated to osteocytes, this type of bone formation is known as intramembranous 
ossification. Osteoblasts initially produce bone during embryonic development and continue 
to metabolise bone during bone growth and remodelling including tissue trauma, such as 
myositis ossificans, whereby calcification occurs within a muscle after trauma or fracture. 
Mature bone is formed by the highly organised mineralisation of the bone matrix secreted by 
the osteoblast cells (Buckwalter et al. 2010). Long bones, however, are formed through 
endochondral ossification; this is whereby the cartilage is initially formed from differentiating 
chondrocytes, and later replaced by bone through morphogenesis (Gerber et al. 1999) 
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Osteoblasts have been shown to produce various growth factors, which are regulated by both 
hormones and local mechanical stress. Growth factors have been shown to increase bone 
formation in vivo by regulating proliferation and differentiation of osteoblasts at different 
stages of the cell cycle and therefore significant for local regulation of bone formation. Bone 
morphogenetic proteins (BMPs) and Insulin-like growth factors (IGFs) are growth factors that 
are involved in the bone modelling process; 
Bone morphogenetic proteins (BMPs) are involved in various development and 
pathophysiological processes of bone formation. BMPs are synthesised by osteoblasts and are 
secreted within the extracellular bone matrix. In vitro, differentiation of mesenchymal stem 
cells (MSCs) into osteoblastic phenotypes occurs in the presence of BMPs. In vivo, BMPs 
initiate the complete pathway of bone formation, starting from the migration of MSCs through 
to the differentiation into osteoblasts (Kempen et al. 2010). 
Insulin growth factors (IGFs) have shown to increase the proliferation and migration of 
MSCs and osteoprogenitor cells in vitro, leading to new bone formation and mineralisation.  
IGFs have an anti-apoptotic effect on pre-osteoblasts and enhance bone matrix synthesis. In 
vivo IGF treatment increased bone formation, bone volume as well as bone turnover in animal 
models and clinical trials for osteoporosis (Niu & Rosen 2005). 
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2.2.2.2 Bone resorption 
Bone homeostasis relies on the delicate balance between bone deposition by osteoblasts and 
bone resorption by osteoclasts. Initial osteogenesis occurs in the embryonic skeleton, and 
hereon osteoblasts and osteoclasts begin the simultaneous processes of bone modelling and 
remodelling. During skeletal growth, bone remodelling takes place at a rapid pace. The rate of 
bone turnover of the skeleton approaches nearly 100% in the first year of life, and decreases 
to approximately 10% per year in early adulthood and remains at this rate throughout life 
(Barrère et al. 2006).  The intercellular communication between both osteoblasts and 
osteoclasts is essential to maintain this balance (Phan et al. 2004).  
Osteoclasts are derived from the haematopoietic cell lines of the macrophage/monocyte 
lineage and are differentiated within the bone microenvironment. Once differentiated, 
multinucleated osteoclasts attach to the bone matrix via integrin receptors and undergo 
various morphological changes. The cells polarise at 4 domains known as; the ruffled border, 
the basolateral domain, the functional secretory domain and the sealing zone, illustrated in 
Figure 2.3. The osteoclasts initiate bone resorption, by degrading the inorganic component of 
the bone matrix, hydroxyapatite. This is demineralised by the acidification of the intercellular 
vesicles known as resorption lacunae, which secrete hydrochloric acid leading to the 
dissolution of the mineral crystal allowing for the digestion of the bone matrix. As the bone 
undergoes resorption, various growth factors such as growth hormone (GH) and transforming 
growth factor – β (TGF-β), within the bone matrix are released at the same time, to recruit 
osteoblasts in the resorbed area as illustrated in Figure 2.3 (Rucci 2008).  
Growth Hormone (GH) functions as a growth factor for bone remodelling in two ways; via 
direct interactions with GH receptors on osteoblasts and via the induction of IGF-1. Direct 
interaction of GH stimulates the proliferation of osteoblasts. In recent in vitro studies, it has 
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been shown that GH also regulates osteoclast formation in bone marrow cultures (Ohlsson et 
al. 1998). In vivo studies have shown that GH administration increases bone formation and 
resorption and thus enhancing bone mass and mechanical strength (Andreassen & Oxlund 
2001).  
Transforming Growth Factor – β (TGF- β) is mainly expressed by osteoclast and 
osteoblasts, and is therefore considered an important regulator for their activity. It has been 
suggested that TGF-β couples both bone formation and resorption during the remodelling 
cycle. It directly enables osteoclast formation by antagonising inflammatory signalling; this 
stimulates a state in which various precursors are resistant to the inflammatory response 
created by the osteoclasts. In contrast the role of TGF-β is also to suppress osteoclast 
formation to prevent excessive resorption. This indirect role of TGF-β is as a result of it 
regulating the osteoblastic signalling pathway, involving RANKL (receptor activator of NFkB 
ligand) expression. An increase in RANKL expression reduces the rate of osteoclastic 
differentiation and therefore reduces the rate of resorption (Fox & Lovibond 2005).  
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Figure 2.3: Schematic representation of the bone remodelling process; Activation phase is  
where bone remodelling begins when lining cells are activated by various signals and 
increase the expression of RANKL. RANKL triggers osteoblast (OBL) differentiation. 
Resorption phase – osteoclasts (OCL) resorb bone and factors stored within the bone matrix 
are released, thus recruiting osteoblasts in the reabsorbed area.  Formation phase – 
osteoblasts produce a new bone matrix and stimulate mineralisation therefore completing 
the remodelling process (Rucci 2008). 
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2.2.3 Molecular biology  
Osteoblasts are continuously developing from a proliferating immature cell to a mature 
osteoblastic cell that synthesises specific bone proteins which are characterised by a specific 
sequential expression of tissue specific genes. These specific genes identify the three distinct 
periods of osteoblast phenotype development; proliferation, maturation and the synthesis of 
the extracellular matrix and matrix mineralisation (Neve et al. 2011). Differentiated and 
mature osteoblasts express the proteins as described below. 
2.2.3.1 Collagen 
Collagen is the most common protein found in nature and is present in many tissues in the 
human body such as bones, skin, lungs and scar tissue as it is the major constituent of the 
extracellular matrix. Collagen has many functions, the major function among them being its 
capacity to mineralise in tissues such as bone, tendon and dentin.  Mineralised collagen acts as 
the framework for the mechanical support as of the skeleton and acts a reservoir for ions and 
small molecules as well as a means of strain energy storage (Landis et al. 2006). 
The defining feature of collagen is the right handed triple helix  formed from a structural 
motif of 3 parallel polypeptide strands in a left-handed, polyproline-II-type (PP-II) helical 
confirmation which coil around each other and is stabilised by hydrogen bonding (Shoulders 
& Raines 2010). The triple helix configuration is made up of repetitive triplet of Gly-X-Y, 
where X is often proline and Y is usually hydroxyproline. Glycine is always required in every 
third position as it is the smallest amino acid that occupies a limited space in the centre of the 
triple helix (Viguet-Carrin et al. 2006). 
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The triple helix form collagen fibrils of approximately 300nm in length and 1.5nm in 
diameter are bordered with short telopeptides. Collagen fibrils are synthesised and transported 
into the extracellular matrix in the form of procollagens - soluble precursors of collagen. The 
biosynthesis of procollagen is a complex process in which several enzymes and molecular 
chaperones assist its folding and trimerisation. Synthesised procollagen chains are associated 
in trimers via their C-propeptides, leading to nucleation and folding in a C-to-N direction and 
forming the triple helix. Protein disulphide isomerase induces the formation of inter and 
intrachain disulphide bonds within the c-propeptide allowing the association between 
procollagen chains (Viguet-Carrin et al. 2006). 
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Figure 2.4: Schematic diagram illustrating the process in which procollagen is converted to 
collagen after it is released from cells (Kadler et al. 1996).  
Procollagen bordered by a trimeric globular C – propeptide domain (right hand side of Figure 
2.4) and the trimeric N-propeptide domain (left hand side of Figure 2.4) is secreted from cells 
and converted to collagen by the removal of the C and N propeptides by procollagen 
proteinases. Once the collagen is formed it spontaneously self assembles into striated fibrils 
that are present in the ECM of connective tissues. These fibrils are stabilised via covalent 
cross-linking which is limited by oxidative deamination of specific lysine and hyroxylysine 
residues in the collagen by lysyl oxidase.    
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Approximately 80% of the total proteins in bone are collagen, whereby 95% of this collagen 
is type 1 collagen. Bone matrix has the unique ability to mineralise, as crystals of 
hydroxyapatite are found on the collagen fibres and within them. The crystals are often 
oriented in the same direction as the collagen fibres. type 1 collagen is known for its 
mechanical function, providing elasticity and structure in bone tissue. Several studies indicate 
collagen plays a key role in its capacity to absorb energy, while the mineral content, HA, is 
mainly involved in determining bone stiffness. 
Abnormalities of collagen structure can be caused by genetic mutations such as osteogenesis 
imperfecta – a disease which causes brittle bones due to the lack of connective tissue, the 
amino acid sequence of type 1 collagen is altered which results in the formation of branched 
fibres responsible for brittle bones and abnormal mineralisation (Rupani et al. 2012).  
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2.2.3.2 Osteopontin 
Osteopontin (OPN) is made up of approximately 300 amino acids and is a negatively charged 
hydrophilic protein, which is acidic in nature. The OPN molecule undergoes considerable 
post-translational modification, and is phosphorylated and glycosylated. OPN has an arginine 
–glycine-aspartic acid (RGD) cell binding sequence, a calcium binding site and two heparin 
binding domains (Mazzali et al. 2002). 
OPN is closely involved in the regulation of both physiological and pathological 
mineralisation and is expressed by both osteoclast and osteoblasts.  OPN influences bone 
homeostasis both by inhibiting mineral deposition, by promoting osteoclast differentiation 
and by enhancing osteoclast activity (Rosenthal et al. 2007). OPN is one of the major non-
collagenous proteins in bone. The electronegative RGD residues and the Ca
2+ 
binding sites 
allow OPN to tightly bind to HA, therefore making OPN a potent inhibitor of the 
mineralisation process. Osteopontin is secreted into all body fluids and plays a key role in 
angiogenesis as well as immune function (Standal et al. 2004). 
2.2.3.3 Alkaline Phosphatase 
Alkaline phosphatase (ALP, orthophosphoric-monoester phosphohydrolase – EC 3.1.3.1) is a 
metalloenzyme which is expressed in various tissues, such as the intestine, placenta, liver, 
kidney and bone. The ALP gene corresponding to the liver, kidney and bone is the tissue- 
nonspecific alkaline phosphatase (TNAP) (Mornet et al. 2001). ALP is anchored to the 
membrane via glycosylphosphatidylinositol (GPI) by means of postransational modification 
(Golub et al. 2007). 
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High levels of ALP are present in bone as it is known to increase the local concentration of 
inorganic phosphate (Pi) (Golub et al. 2007). ALP is among the first non-collagenous genes 
expressed in the process of calcification, as it hydrolyses inorganic pyrophosphate (PPi) to 
generate Pi, which stimulates the formation of hydroxyapatite. ALP expression is therefore a 
good predictor neotissue osteogenesis (Orimo 2010) 
Mutations on the TNAP gene have been linked with hypophosphatasia a rare inherited bone 
disease, which is characterised by hypomineralisation of hard tissues (Whyte 2010). 
2.2.3.4 Osteocalcin 
Osteocalcin (OCN) makes up 25% of the non-collagenous proteins of the bone matrix. It is a 
highly conserved (has the same sequence in most invertebrates) extracellular protein 
composed of 49-51 amino acid residues, with a molecular weight of 5-6kDa (Lepage et al. 
1990). Its transcription occurs in three steps, initially it is regulated by 1,25 – dihydroxy – 
vitamin D3, here the molecule is made up of 3 parts, a signal peptide cleaved during 
translation, a propeptide which targets the protein for γ-carboylation and a mature protein. 
The second step involves translation of osteocalcin by vitamin K1, this acts as co-factor for 
the post-translation γ-carboxylase enzyme, this is where a second carboxyl group is added to a 
specific glutamyl residue (Glu) forming γ-carboxyglutamyl residues (Gla). This modification 
stabilises the osteocalcin protein and promotes its binding to calcium and hydroxyapaptite 
(Lee et al. 2000). Osteocalcin has also shown to delay nucleation of HA (Hunter et al. 1996) 
and therefore acts to regulate bone remodelling, previous studies have shown that mice 
deficient with respect to OCN have increased bone formation (Ducy et al. 1996).  
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2.2.3.5 Osteonectin 
Osteonectin is a 32kDa protein expressed by osteoblastic cells. It is a single chain polypeptide 
containing two glycosylation sites that can bind up to eight Ca
2+
 ions making it a protein that 
binds strongly to hydroxyapatite. In the presence of high concentration of hydroxyapatite, 
osteonectin has the ability to inhibit HA crystal growth, this may aid in the remodelling of 
bone tissue. Osteonectin is also significantly present in non-mineralising tissues such as 
platelets and endothelial cells therefore its function cannot be limited to calcified tissue (Kelm 
et al. 1994). Osteonectin is present in the basement membrane matrix of actively proliferating 
and remodelling sites such as embryonic and adult tissues. It is also shown to bind to type 1 
collagen (Termine et al. 1981), it is therefore suggested that osteonectin is involved in cell-
matrix interactions rather than mineralisation directly (Termine et al. 1981). 
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2.2.4 Bone mineralisation and development of the skeleton 
The inorganic mineral, hydroxyapatite makes up nearly 70% of calcified bone. 
Hydroxyapatite is a calcium phosphate mineral with a chemical formula Ca10(PO4)6(OH)2. Its 
morphology is mainly plate-like with a length of 30-50nm.  Early X-ray fluorescence 
spectroscopy patterns show that crystalline HA has a Ca/P ratio of 1.67, however, it has 
recently been demonstrated that this ratio may vary in biomineralised HA as bone is 
continuously being remodelled to maintain homeostasis with regards to calcium, phosphate 
and magnesium ions (Palmer et al. 2009).    
 
Figure 2.5: HA mineral and non-collagenous proteins can be found in-between and within 
collagen fibres (McNamara 2011) 
Prior to osteoid mineralisation the organic matrix primarily consists of collagen, non-
collagenous proteins such as osteocalcin, osteopontin and osteonectin as well as growth 
factors and signalling molecules (Figure 2.5). The organic matrix starts to mineralise 10-15 
days after it has been synthesised in the collagen fibrils (Sommerfeldt & Rubin 2001).  
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The mineralisation process is initiated by matrix vesicles, which are 30-100nm in diameter 
and are lipid bi-layer organelles originating from chondrocytes or osteoblasts. Matrix vesicles 
are made up of several proteins such as alkaline phosphatase and annexins II, V and VI. 
Annexin V plays a key role in the functioning of matrix vesicles especially during the 
beginning of calcification when the first HA phase is formed in the vesicle lumen. Annexin V 
causes an influx of Ca
2+
 ions into the vesicle which therefore results in the mineral growth 
form the existing nucleation complex. Inorganic ions Ca
2+
 and inorganic PO4
3-
 are 
accumulated within the matrix vesicles as shown in Figure 2.6. Annexin V also binds to 
collagen types II and X; this facilitates the anchoring of the vesicles to the extracellular 
matrix. The vesicles’ membrane ruptures and releases HA crystals into the extracellular fluid, 
where they further grow and spread and become part of the ECM. The balance between PO4
3-
 
to crystalline HA is regulated by the extracellular P2O7
4-
 (pyrophosphate), which inhibits the 
ability of PO4
3-
 to crystallise in the presence of calcium(Sapir-Koren & Livshits 2011). 
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Figure 2.6: Electron micrographs of matrix vesicles exhibiting needle-like crystal structures of 
HA therefore indicate the process of calcification. Bar denotes 100µm (Kirsch et al. 1997). 
Various studies have been carried out to investigate the structure and the components that 
begin mineralisation, it has been suggested that the presence of proteoglycans in the cartilage 
may also provide these nucleation sites. In this mechanism mesenchymal stem cells are 
differentiated into chondrocytes to form a firm model of the cartilage. The proteoglycans have 
a high negative charge density which allows them to bind a significant amount of Ca
2+ 
ions, 
which are then displaced by inorganic phosphate leading to mineral deposition into the 
collagen matrix which acts as a scaffold for the growth of bone (Kirsch et al. 1997)   
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2.2.5 Bone fracture and healing  
Although bone has the innate ability to remodel and repair itself through a lifetime, some 
traumatic injuries and pathological diseases such as osteoporosis, osteogenensis imperfecta 
and Paget’s disease, can result in a loss of these normal functions, which increase the 
likelihood of bone fractures.  Fracture healing is a process that takes place with the assistance 
of osteoprogenitor, chondroblast and osteoblast cells (McNamara 2011).  
The fracture healing process is similar to that of bone formation in the embryo indicating that 
similar mechanisms occur for both bone formation in mature bone and embryonic skeletons. 
Bone formation occurs in two processes, intramembranous and endochondral ossification, 
depending on the type of bone being formed. Intramembranous ossification occurs when a 
high concentration of mesenchymal cells are transformed into osteoprogenitor cells and 
immediately into osteoblasts, leading to the direct formation of bone. Endochondral 
ossification, on the other hand occurs via a two-step process, whereby, initially the 
mesenchymal cells are differentiated to chondroblasts, which produces the collagenous 
template which is ossified by osteoblasts (Hing 2004).  
Bone healing usually occurs via the endochondral ossification process. A bone fracture 
initially leads to the formation of a haematoma (blood clot) which occurs because of injury to 
the periosteum. The periosteum consists of blood vessels and is the area of bone where soft 
tissues, tendon and muscle attach. In response to the haematoma, inflammatory cells are 
recruited to the site. The inflammatory response is linked with pain, heat, swelling and the 
release of several growth factors and cytokines at the site of fracture. Bone repair begins 3-7 
days after the inflammatory response this is whereby the cells present at the damaged site start 
to differentiate into either osteoblasts or fibroblasts (Carano & Filvaroff 2003).  
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Cells such as macrophages and fibroblasts are also recruited so as to remove the tissue debris 
and to express the extracellular matrix proteins, respectively. Osteoblasts begin to produce 
woven bone, which rapidly produces a periosteal and marrow callus. The soft callus fills the 
gaps of the fracture as illustrated in Figure 2.7.  
 
Figure 2.7: Schematic diagram illustrating the processes of bone healing. As a result of 
injury, blood vessels are damaged and a haematoma forms (a). Angiogenesis occurs and a 
soft callus is formed (b). The soft callus starts to calcify forming woven bone (c). The 
fractured site starts to remodel to recapitulate the original bone (Carano & Filvaroff 2003). 
Fibroblasts induce angiogenesis within the granulated site and chondrocytes form the 
collagenous cartilage.  The woven bone is remodelled into lamellar bone and by the process 
of endochondral ossification the cartilage is converted to mineralised tissue. The newly 
formed callus is constantly being remodelled by osteoclasts until the bone reaches its original 
morphology and mechanical strength and stiffness (McNamara 2011).   
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2.3 Tissue Engineering  
Every year there are approximately 20,000 organ transplants and around 2 million 
implantations of organs and parts (Nerem & Sambanis 1995). There are not enough organs, 
however, available for transplantation, which leads to patients dying with some not even 
making the organ waiting list. Consequently, this has led to an increase in the demand for 
‘artificial’ organs and biomaterials that cannot be met by transplantation on its own.  
Tissue engineering is a multidisciplinary research field that focuses on the formation of 
biomaterials used for repairing/treating of damaged or diseased tissue. Medicine, biology, 
material science and engineering all play vital roles in the development of an ideal scaffold to 
be implanted in the body.  The main aim of tissue engineering is to overcome the limitations 
encountered during conventional treatments based on organ transplants. Tissue engineering 
can potentially lead to the supply of tissue substitutes which can be tolerated by the immune 
system and last a lifetime with a patient. Tissue engineering is a permanent solution in 
treating organs or tissues, without the need for additional treatments and therefore making this 
a cost effective treatment over a longer period (Sachlos & Czernuszka 2003).  
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2.3.1 Bone tissue engineering 
As previously described, bone has the unique ability to restore to a healthy tissue depending 
on the size of a fracture or defect  (Hing 2005). Pathological condition such as cancer or 
degenerated bone due to age or disease however, can often only be restored by surgical 
procedures. Bone grafting was first recognised in the 1800s, whereby damaged or diseases 
bone was either replaced by autografting, that is when a healthy tissue is taken from the 
patient’s own body, or allografting, a healthy tissue obtained from a donor (Lavernia et al. 
2004).  
 Autografting is often used in orthopaedics; however this is restricted by the amount of bone 
that can safely be removed from the patient. Other disadvantages include, the demand for 
healthy bone often exceeds the supply and healing can often be inconsistent. Consequently, 
this has led to an increase in the demand for biomaterials-based treatments that would avoid 
these complications.   
Initially the materials created were designed to act as load bearing scaffolds only, however 
material scientists have now moved to forming bioactive materials that can be combined with 
biological molecules to promote tissue regeneration (Stevens 2008).  
An ideal material for bone regeneration should exhibit load bearing mechanical properties that 
are suitable for the desired site of implantation which is often determined by its porous 
structure. The scaffold being designed as a bone replacement composite must be able to 
provide the mechanical stability to the constructs in load bearing sites prior to the deposition 
of the extracellular matrix by the cells. A scaffold with an interconnected porous structure 
with a high porosity but less than 90% allows for the cells to penetrate through the material as 
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well as allowing for tissue in-growth and making nutrients available to the new tissue being 
formed.  
Often biomaterials produced for bone tissue engineering act as a cell delivery scaffolds 
whereby the material is able to support cells as well as promote attachment, proliferation and 
differentiation of the osteogenic cells. As new bone tissue starts to develop around the 
scaffold, appropriate degradation of the composite in vivo is required so as to promote tissue 
regeneration. Another key characteristic for bone replacement therapies is the ability to tailor 
the scaffold, that is, the material should be adaptable and easily malleable so as to be 
incorporated into various shape defects, which are indeed unique to each patient.  
Many bone substitutes are designed to substitute autologous or allogenic bone replacements 
and the most common bone biomaterials investigated are; bioactive ceramics, bioactive 
glasses, biological and synthetic polymers and various composites of these (Stevens 2008).   
2.4 Trace elements in bone 
The importance of trace elements was first noticed during the 19
th
 century when zinc was 
identified in micro-organisms such as Aspergillus niger and later the relevance of iron in 
haematopoiesis and anaemia was discovered (Prasad 1991). In the late 1970s it was noticed 
that trace elements also play an essential role in bone architecture. These trace elements 
include; silicon (Si), copper (Cu), manganese (Mn) and zinc (Zn) (Calomme et al. 2006). 
Although various cellular and molecular markers influence the synthesis and maintenance of 
bone, trace elements play an essential role in bone metabolism and act as cofactors for 
specific enzymes (Towler et al. 2009). In this section the role of silicon in bone biology and 
its addition into various biomaterials is discussed.   
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2.5 Silicon 
2.5.1 Silicon in the environment 
Silicon is the second most abundant element in the Earth’s crust at 28% wt, when combined 
with oxygen it forms silicates which form the largest and most abundant groups of minerals 
(Anvir et al. 2006). Silicon dioxide (SiO2) is often in the form of ordinary sand; however it 
also exists as quartz, rock crystal, rhinestone and opal (Douthitt 1982). It is also the main 
element of glass, cement and some ceramics.  
2.5.2 Diatoms and radiolarians 
The silicon mineral in the form of hydrated amorphous silica is one of the major minerals 
made by organisms, after carbonate minerals which occur in abundance. Amorphous silica 
plays a significant role in most plant biology, as its primary function is to strengthen cell 
walls for support and to provide skeletal functions for protection such as in radiolarian and 
diatoms (Figure 2.8).  
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Figure 2.8: Images of; (a) silica cells from higher plants such as Oryza sativa a type of rice, 
which can be up to 7µm in diameter. (b) The structure of radiolarians and diatoms which 
can be nearly several hundreds of micrometres in diameter. (c) Silicified cell wall stromal 
structures from Equistetum arvense a field horsetail at 20µm in diameter (Perry 2010). 
Diatoms are single celled organisms that have the most unique feature of their highly 
organised siliceous walls. The presence of silicon in these microorganisms is vital for 
photosynthesis and metabolic processes such as the synthesis of proteins and DNA, whereby 
the cell cycle is dependent on the presence of amorphous silica (Theriot et al. 2012).        
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2.5.3 Silicon in higher animals 
Silicon was an overlooked trace mineral until the late 1970s, and was considered to be inert in 
the biological system. It is, however, proving to be an essential component in the human 
body, for maintaining bone and skin health. Humans store nearly 2-5g of silica in various 
tissues and body fluids. Silica binds via glycosaminoglycans in tissues and is found as 
orthosilicic acid in the blood. The main source of silicon for the human body is predominantly 
from the diet, these include; drinking water containing orthosilicic acid, the ingestion of 
plants and animals as well as drinking beverages such as beer (Jugdaohsingh et al. 2002).  
Animal studies in the in the 1970s showed that dietary silicon is necessary during the 
mineralisation process of growing bone (Carlisle 1976; Schwarz 1973). Various research 
groups over the last 30 years have added to these findings and show that dietary silicon is 
important for formation and bone health.  
2.5.4 Silicon is essential for bone formation 
In vivo studies conducted by Carlisle (1975), found that silicon is required for normal growth 
and development in the chick. From this study it has been suggested that silicon is associated 
with calcium in an early stage of bone formation. The Carlisle study showed that chicks fed 
on a diet without silicon had a decreased growth rate, when compared to chicks fed on a 
supplemented diet. The chicks on the non-supplemented diet appeared to much smaller and 
stunted. The bones of the deficient birds show a smaller circumference and a thinner cortex, 
and also tend to fracture easily. The beak and comb were also more flexible in the deficient 
group, shown in Figure 2.9. These findings strengthen the fact that silicon is vital in early 
bone formation.  
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Figure 2.9: Four week old chicks showing normal growth when silicon is present in the diet 
(left) and abnormal growth in a non-silicon diet (right), (Carlisle 1972). 
In vivo experiments were also carried out on rats which concur with the results from the 
chicks’ study, where the relationship between silicon and calcium in bone formation was 
investigated (Schwarz 1973). Schwarz et al (1973) showed that silicon is involved in the 
development of the glycosaminoglycan network, by forming cross-links via silanolate 
bonding (R-O-Si-O-R) which stabilises the structure and function of the polysaccharide. 
Silicon has been identified within early bone growth in young mice and rats and its 
concentration increases simultaneously with the increase in calcium concentration, within the 
bone matrix. It has been noticed, however, that as the bone matures with time the levels of 
detectable silicon decrease as the bone becomes fully mineralised. This suggests that silicon is 
essential in the initial growth of the organic matrix and may act as an initiator for the process 
of calcification.   
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2.5.5 Polymerisation of silicon 
Silicon on its own is an insoluble solid, and is mainly present as an oxide, most commonly 
known as silica (SiO2), which is also just partially soluble in water. Silica at pH 10, however, 
is present as silicate ions which are soluble in water, and hydrolyses to form orthosilicic acid. 
Orthosilicic acid in solution exists as Si(OH)4, formed from silica (Equation 2-2).  
SiO2 (S) + 2H2O(l)  Si(OH)4 (aq)  
Equation 2-2 
Orthosilicic acid is highly hydrophilic and is difficult to isolate, because it is a weak acid that 
exists in dilute aqueous solutions as it polymerises when it is concentrated. It is the soluble 
form of silica that is in equilibrium with the solid phase. It has been demonstrated that the 
acid dissociates in two steps when in the presence of water (equation 2-3); 
Si(OH)4 + H2O  SiO(OH)3
-  + H3O
-  Pka= 9.8 
Si(OH3)
- + H2O  SiO2(OH)3
- + H3O
-  Pka= 11.8 
Equation 2-3 
(Greenberg 1959) 
Orthosilicic acid ionises in alkaline solutions at approximately pH 10, in the presence of 
hydroxyl ions (Equation 2-4), 
Si(OH)4 + OH
-  HSiO3
- + 2H2O 
Equation 2-4 
(Iler 1955) 
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The condensation of silanol groups leads to polymerisation, and as polymerisation continues 
it forms hydrated colloidal particles which have a higher affinity with organic molecules and 
can form complexes with inorganic compounds, for example, aluminium and calcium oxide.   
The solubility of orthosilicic acid increases as the temperature increases (Figure 2.10), it was 
demonstrated that amorphous silica solubility occurs at 100
o
C (Rimstidt & Cole 1983), 
however later found that it dissolves at even higher temperatures of 350
o
C (Gunnarsson & 
Arnỏrsson 2000).  
 
Figure 2.10: Determination of the solubility of amorphous silica and quartz was carried out 
at various temperatures and showed that at 100oC amorphous silica and quartz started to 
dissolve and form orthosilicic acid (A) (Rimstidt & Cole 1983). This has been confirmed by 
various other researchers (B) (Gunnarsson & Arnorsson 2000). 
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2.6 Silicon containing biomaterials 
There is a constant increase in the number of people who suffer every year from bone traumas 
and diseases (Harvey et al. 2010). Autografts and allografts are the ‘gold standard’ procedures 
often used to treat/repair the damaged bone. These grafts however, possess various risks for 
example the risk of disease transmission and implant failure, particularly if being applied for a 
long time. This has led to an increased interest in fabricating synthetic bone substitutes, which 
can eliminate these risks and enhance bone growth onto the implanted surface. Materials such 
as metals and cements have been used extensively, as they exhibit ideal properties for bone 
replacement. During the past two decades, however, these biomaterials have also been used 
for drug delivery by inserting bioactive components within the material to enhance the growth 
of new bone. In this section, materials containing silicon as a bioactive agent have been 
discussed, the most popular of them being hydroxyapatite, Portland cements, Bioglass® and  
natural and synthetic polymers.  
2.6.1 Silicon substituted hydroxyapaptite 
Synthetic hydroxyapatite, a hydrated calcium phosphate is the most commonly used 
biomaterial in bone and dental applications (Gibson et al. 1999), and has been used as a 
coating on hip replacements and as acts a filler in bone cavities (Barrère et al. 2006). It has a 
similar composition and crystallographic structure to the natural bone mineral; it is also an 
osteoconductive material, as it supports the attachment of new osteoblasts and therefore 
allows direct bone formation across its surface by attachment, proliferation and differentiation 
of bone cells (Patel et al. 2002).  
Natural bone mineral often contains various ionic substitutes in its lattice, which most 
synthetic HA composites do not have, this therefore makes synthetic HA less integrated with 
natural bone tissue, when implanted. This limitation can be overcome by substituting ionic 
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components such as silicon within the lattice as it plays a significant role in the biochemistry 
of tissue growth. One of the early fabrications of silicon substituted HA (Si-HA) was carried 
out by Gibson et al (1999), whereby Si-HA was formed by a simple aqueous precipitation 
method and sintered at 1200
o
C which resulted in HA without any secondary phases such as 
calcium oxide and tricalcium phosphate. This method substitutes phosphate in the HA lattice 
with silicate (Gibson et al. 1999).  
In vitro studies carried out by Thian et al (2006) coated titanium (Ti) surfaces with Si-HA and 
compared the response of human osteoblast cells (HOB) to nanocrystalline Si-HA thin 
coatings of different silicon compositions and that of uncoated titanium surfaces. There was a 
significant increase in cell growth density, including differentiation and it was found that cells 
on the silicon coated surfaces formed an extensive extracellular matrix and bone minerals 
were also observed on cell membranes. High concentrations of silicon coating (4.9%), 
however showed to inhibit cell attachment as it was noticed there was fast dissolution of Si 
from the material, which was not ideal for cells at the early time points (Thian et al. 2006).  
The in vivo behaviour of Si-HA was demonstrated by Patel et al (2002) where they fabricated 
granules of pure phase HA and Si-HA and assess the bone growth of the granules. It was 
shown that Si-HA increased in vivo bone growth when compared to phase pure HA granules. 
This strengthened the evidence the silicate ions in low concentrations are an improved 
alternative to just phase pure HA for bone tissue engineering (Patel et al. 2002) 
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2.6.2 Bioactive glass ceramics 
Bioactive glass ceramics were first discovered by Hench et al in 1969, whereby it was noticed 
that when the phosphosilicate glass was implanted it joined with bone without forming a 
fibrous scar. The bioactive glass was trademarked Bioglass 45S5
®
 and is formed from 45% 
SiO2, 24.5% Na2O, 24.5% CaO and 6% P2O5 wt% (Xynos et al. 2000). Bioglass® has been 
classified into the Class A bioactivity index as they exhibit both osteogenic and 
osteoconductive properties. They also have the ability to bond to both bone and intramuscular 
sites (Lai et al. 2002). This led to a series of experiments whereby the surface chemistry of the 
glass ceramic was evaluated and in vitro investigations carried out to determine the effect of 
this bioactive glass on a cellular level.     
 In vitro analysis showed that Bioglass 45S5
®
 has an effect on the cell cycle of human 
osteoblast cells  resulting in an increase in osteoblast turnover, which produces a population 
of mature bone cells leading to the formation of bone nodules in a relatively short time of 12 
days (Xynos et al. 2000). This is due to the dissolution of various ions from the glass ceramic 
which also contains a surface gel consisting of calcium phosphate and reactive silica, which 
leads to the formation of bone-like tissue.    
Bosetti et al (2002) studied the effect of three bioactive glass composites containing various 
amounts of silica on HOB cell behaviour, focussing especially on the expression of collagen 
and the matrix associated non-collagenous protein alkaline phosphatase. It was demonstrated 
that there was a significant increase in collagen secretion by the osteoblasts when cultured on 
the Bioglass 45S5® surface. It has previously been suggested that the cross-linking of 
collagen chains and the precipitation of hydroxyapatite are pH dependent. The dissolution of 
the glass ceramic caused alkalisation in the culture media, and since collagen formation is pH 
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dependent, increased the production of collagen and crosslinking as well as increasing the 
formation of hydroxyapatite (Bosetti et al. 2003).  
2.6.3 Calcium phosphate cements and Portland cements 
Calcium phosphate ceramics have been the most common biomaterials used as exogenous 
grafts in bone regeneration. Calcium phosphate as a biomaterial in both bone and dental 
applications has the unique characteristic for bone substitution when compared to other 
biomaterials as its chemical composition is similar to that of the biological bone mineral, 
apatite. Calcium phosphates also known more accurately as calcium orthophosphates, are salts 
of orthophosphoric acid (H3PO4). The advantages of using calcium phosphate cements  is that 
they are self-hardening and are able maintain sufficient mechanical strength for repairing 
damaged hard tissues (Guo et al. 2007). The limiting factors of calcium phosphates, however, 
are the unpredictable setting times and degradability (Verron et al. 2010). 
Synthetic calcium phosphates such as α- or β- tricalcium phosphates (α- or β- TCP) and 
biphasic calcium phosphates (BCPs) are widely used as biomaterials in bone tissue repair. β-
TCPs are bioresorbable ceramics that are well tolerated in the body and have shown to be 
osteoconductive. In vivo, however, β-TCP, shows a reduced rate of bone formation and 
osseointegration, this limits its potential use as a bone replacement biomaterial. To enhance 
the function of the β-TCP, Ni et al (2007) synthesised calcium silicate, (CaSiO3, CS, Portland 
cement) and β-TCP composites and evaluated apatite formation and in vitro response of 
osteoblasts  to the composite (Ni et al. 2008). β-TCP/CS composites increased in mechanical 
properties such as compressive strength and bending strength when compared to β-TCP 
composites only. In vitro cell cultures showed increased adhesion, growth and ALP activity of 
the osteoblast cells when cultures on the modified composite containing 50% CS. 
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In vivo experiments with calcium silicate have shown that dissolution of both calcium and 
silicon ions from the material improved osteogenesis, by having a direct effect on the genes 
which regulate the induction and progression of the cell cycle (Guo et al. 2007). 
2.6.4 Natural and synthetic polymers 
 Natural and synthetic polymers are widely used in tissue engineering, as scaffolds, in 
orthopaedic surgery such as rods, screws and pins and sutures, cell delivery carriers and drug 
delivery vesicles. Naturally derived polymers are often used as they have a similar structure to 
the ECM and do not cause inflammation or immunological reactions and toxicity within a 
biological environment (Mano et al. 2007).  
Biodegradable synthetic polymers have a number of advantages such as; their mechanical 
properties and degradation properties can be altered to suit for their desired application. 
Desired pore sizes as well as shapes can also be achieved that will allow for its specific 
application. Chemical functional groups can also be incorporated within the polymers so as to 
induce tissue growth (Gunatillake & Adhikari 2003). 
Biopolymers such as chitin are widely investigated as scaffolds in bone tissue engineering. 
Chitin is a biopolymer composed of β -1,4 glycan of N-acetyl – D – glucosamine units and is 
present in two crystalline forms, α – chitin and β – chitin. Chitin is used in various 
applications like wound dressings due to its wound healing, antibacterial and anti – 
inflammatory properties. Although chitin has various properties such as biocompatibility, 
biodegradability, non- toxicity and haemostatic property, it is not a bioactive material and 
therefore cannot induce bone regeneration. Madhumathi et al (2009), show that the addition of 
silica can improve the bioactivity of chitin in vitro using stimulated body fluid (SBF) it was 
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seen that the crystalline hydroxyapatite was formed on and in the scaffolds after being 
immersed in SBF for 14 days (Madhumathi et al. 2009). 
Lee et al hybridised chitosan with a silica xerogel to form a chitosan – silica xerogel hybrid 
membrane. Silica xerogels act as biologically active agents and are useful as a bone substitute 
and drug delivering particulate carrier. The chitosan – silica xerogel hybrid membrane has 
shown excellent ability to form bone like apatite. The faster mineralisation of the hybrid 
membrane releases ions which induce degradation of the membrane. Calcium and 
phosphorous ions lead to the supersaturation of the SBF solution around the hybrid membrane 
and this increased the formation of apatite. The chitosan-silica xerogel hybrid membrane 
showed a higher degradation rate than that of pure chitosan membrane, this is observed in in 
vitro tests. The hybrid is also seen to increase the bone healing process and also plays a 
positive role in the stimulation of bone forming cells (Lee et al. 2009).  
Sodium alginate is a linear polysaccharide derived from brown seaweed composed of (1-4) 
linked β-D-mannuronic acid (M unit) and α-L-guluronic acid (G unit) (for further information 
see section 4.1.1*). It has often been used for the encapsulation of cells and biomolecules as it 
forms a soft gel matrix under mild conditions. Alginate’s internal structure resembles that of 
the extracellular matrix, and is often used as a synthetic ECM in tissue engineering and as a 
cell delivery vehicle, organising the cells in a three-dimensional hydrated structure (Rowley et 
al. 1999) keeping them viable and maintaining a normal cellular function in order to produce 
the desired tissue found in the body(Hunt et al. 2010)        
Lim et al (2009), developed silica-coated alginate beads and encapsulated proteins in vitro. 
The silica coat provided the alginate beads with a protective shield resistant to chemical and 
environmental stresses. The silica beads prevented the beads from disintegration and 
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maintained the activity of the proteins encapsulated within the alginate beads for 70h, which 
was five times longer than the length of activity on the non-coated beads (Lim et al. 2009).  
This external membrane prevents leakages of the biological components such as cells, which 
have been entrapped, however did not prevent the diffusion of essential ions into the beads. 
Type 1 collagen has recently been used as a biomaterial in bone regeneration, since collagen 
is the most abundant protein in mammals and it forms most of the structural framework for 
tissues. It is an ideal hydrogel to be used in bone regeneration due to its practical aspects, that 
is, it is easy to prepare as well as having a widespread occurrence in nature. Collagen has 
ideal characteristics as a biomaterial as it gradually degrades in the body as it is being 
replaced by the host tissue (Stenzel et al. 1974), it also has a high affinity for water, low 
antigenicity, and is virtually non-toxic in vivo which favour its use as a biomaterial. Collagen 
also has also shown to promote cellular attachment, growth and differentiation (Landis et al. 
2006). Heinemann et al (2007) developed a silica-collagen xerogels to be an alternative 
scaffold used in hard tissue. The xerogels showed structural homogeneity and sufficient 
mechanical strength as well as supporting the attachment, proliferation and osteogenic 
differentiation of human mesenchymal stem cells (Heinemann et al. 2007).  
The local release of drugs in a desired site is one of the major on-going research areas in 
orthopaedics. The advantage of using localised drug delivery means that the drug can be 
maintained at the desired therapeutic range with just a single dose, without being toxic or 
ineffective. Polymers such as poly-є-caprolactone (PCL), poly lactic-co-glycolic acid (PLGA) 
and polylactic acid (PLA) have been combined with ceramics and are widely used as drug 
delivery mechanisms for bone filling due to their ability to integrate with bone. The main 
disadvantage encountered with using localised drug delivery is when the drug ‘particles’ are 
adhered within the polymer matrix, this causes initial  ‘dumping’ of the drug within the 
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localised area and hence does not allow for a  sustained delivery of the drug, for more than a 
few days.  
To overcome the disadvantage of an initial burst release of drugs once implanted in the 
desired site, Xue et al (2004), formed PLGA/mesoporous silica composites for the sustained 
delivery of the antibiotic gentamicin. Gentamicin was entrapped in mesoporous silica 
particles and then encapsulated in PLGA. The release of gentamicin was more sustained in the 
hybrid structure, that is, PLGA/mesoporous silica composites, than that of mesoporous silica 
alone. The release lasted for up to 5 weeks and more importantly the initial burst of release 
was reduced significantly in the hybrid structure (Xue & Shi 2004). Another advantage of 
having mesoporous silica within the composite is the release of orthosilicic acid as the 
particles degrade. This promotes mineralisation by increasing the deposition of calcium as 
well as neutralising the acidic by-products of PLGA therefore creating an ideal environment 
both in vitro and in vivo (Fan et al. 2012). 
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2.7 Aims of this investigation  
The overall aim of the research presented here is to develop a controlled release system for 
the release of silicon in the form of orthosilicic acid as a potential biomaterial to be applied in 
bone tissue engineering. 
The primary aims of this investigation include; 
 To elucidate the biological pathway of orthosilicic acid on osteoblast cells and in vitro 
mineralisation. 
 To fabricate a release system for the dissolution of a therapeutic dosage of orthosilicic 
acid after evaluating the ideal concentration of orthosilicic acid required for cell 
survival. 
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3. In vitro assessment of orthosilicic acid on osteoblast 
behaviour  
3.1 Introduction 
Nutritional silicon deficiency leads to skeletal deformities such as abnormal skull 
development and long bones, as well as poorly formed joints with decreased cartilage content 
(Perry & Keeling-Tucker 1998). Absorption studies have shown that 50% or less of 
bioavailable orthosilicic acid is absorbed in humans in any ingested dose. Normally fasting 
concentrations of Si in plasma are 2-10µM and rise to 20-30µM after meals and 700µM/day 
are excreted (Reffitt et al. 2003).  The earliest work on the role of silicon in bone dates back to 
the early 1970s where it has been reported that silicon at 0.5wt% in vivo was present within 
the active mineralising osteoid regions, that is, the sites undergoing active calcification. 
Abnormal shaped bones and inadequately formed cartilagenous tissue were formed with lack 
of Si in the diet of new born chicks and rats (Carlisle 1976; Schwarz 1973), however, this was 
reversible upon the addition of soluble Si to their diet. This suggested that silicon may play a 
key role in the metabolism and stabilisation of the connective tissue present in bone and 
cartilage although its effect on calcification may be an indirect phenomenon through its 
interaction with matrix components.   
Although the addition of silica into various biomaterials has been carried out for several 
decades, the optimum concentration of orthosilicic acid required for cell mineralisation in 
vitro, is yet to be established. The dissolution of silicon from these biomaterials into the local 
environment could affect protein secretion, cell survival and apoptosis. Reffit et al (2003) 
demonstrated that type 1 collagen synthesis in human osteoblast-like cells was enhanced in 
the presence of 10-20µM of orthosilicic acid (Reffitt et al. 2003). Arumugram et al showed 
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that 5 to 50µM of orthosilicic acid significantly increased the expression of type 1 collagen 
mRNA in osteoblasts, however the concentration – response relationship is still debated as 
well as the significance of Si in cell behaviour (Arumugam et al. 2003).   
In this chapter a series of experiments were carried out to evaluate the response of osteoblasts 
to 0, 5 and 20 µg/ml concentrations of orthosilicic acid prepared using sodium metasilicate. 
The cell viability and mineralisation was established in osteoblasts, followed by the effect of 
OSA on various osteogenic markers when cells were cultured with osteogenic mediators or 
without osteogenic mediators. Collagen fibrillogenesis was also evaluated with various 
concentrations of OSA.  
3.2 Materials and methods 
3.2.1 Cell isolation and cell culture 
All cell culture procedures were conducted in aseptic conditions within a laminar hood (BSB 
3-S, Gelaire ICN Biomedicals, UK). Equipment was disinfected with 70% ethanol.  
3.2.1.1 Culturing MC-3T3-E1  
Transformed mouse calvarial osteoblasts (MC3T3-E1) were obtained from LGC (Middlesex, 
UK) and stored in liquid nitrogen (N2). When needed the cells were thawed rapidly in a water 
bath at 37
oC and added into fresh Dulbecco’s Modified Eagle’s Medium (DMEM) 
supplemented with 10% foetal bovine serum (FBS), 2.5% HEPES, 1% 
penicillin/streptomycin (P/S), 2.5% L-glutamine (L-Glut) and centrifuged at 1000rpm for 
3min. The old medium was aspirated and discarded, and replaced with fresh supplemented 
DMEM (s-DMEM), the cells were suspended evenly in the culture media and seeded in 75ml 
flasks and maintained at 37
o
C in a humidified atmosphere of 95% air and 5% CO2 (Sanyo 
Electric Co. LTD, Japan) 
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3.2.1.2 Isolation and culturing of rat bone marrow cells 
Rat bone marrow cells (rBMCs) were isolated from the femora of adult albino Wistar rats 
using the method described by Maniatopolous et al (Maniatopoulos et al. 1988). The femora 
were dissected out and the adherent soft tissue was removed. The femora were placed in 
transport medium consisting of: Minimum Essential Medium (α-MEM), 10% P/S, 2.5% 
HEPES and 1% amphotericin, until required. The epiphyses were removed and the femora 
were flushed with supplemented α-MEM containing, 10% FBS, 2.5% HEPES, 10% P/S, 10% 
L-Glut and 1% amphotericin. The cells were centrifuged at 1000rpm from 3min to form a 
pellet of cells. The supernatant was aspirated and replaced with fresh supplemented medium. 
The cells were incubated in a 75ml flask in a humidified atmosphere of 95% air and 5% CO2 
at 37
o
C. The media for all cultures and experiments was changed three times weekly.  
3.2.2 Determining the optimum concentration for cell survival 
MC-3T3-E1 cells at passage 15 were dissociated from the flasks with 0.25% trypsin – 0.02% 
EDTA (Sigma, UK). Trypsin-EDTA was dispensed into the flasks to completely cover the 
monolayer of cells and placed in an incubator at 37
o
C for 3 minutes, until all the cells had 
detached from the surface of the flask, excess culture media was added to the detached cells to 
de-activate the trypsin. The cells were centrifuged at 1000rpm for 3 minutes before re-
suspension in S-DMEM at a density of 2x10
4
cells/ml. The cells were seeded in a 12 well plate 
and left to attach overnight. After overnight attachment, s-DMEM containing various 
concentrations of sodium metasilicate solution was added to the cells. Viability was assessed 
using either the MTT assay (section 2.2.3), calcein AM and propidium iodide staining 
(section 4.2.4) or trypan blue as described in section 2.2.5. The MTT assay and trypan assay 
were used to obtain quantitative data whereas calcein AM and propidium iodide staining was 
used to obtain qualitative data.   
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3.2.3 MTT assay 
The MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assay is a 
colourmetric assay used to assess viable cells number in proliferation and cytotoxicity studies. 
MTT is based on the cleavage of the yellow tetrazolium salt to form a soluble blue formazan 
salt by mitochondrial enzymes. The amount of formazan produced is directly proportional to 
the number of living cells present during the MTT exposure.  
A stock solution of sterile – filtered 5mg/ml MTT (Sigma, UK) in phosphate buffer saline 
(NaCl 138mM; KCl 27mM, PBS (Sigma, UK) was prepared and stored at 4
o
C in the dark. 
10% volume, of the MTT stock solution was added to the cells for analysis. In this case 
200µL of the MTT stock solution was added to the cell cultures and incubated for 4 hours at 
37
o-
C for the formation of the purple formazan crystals. The MTT solution was removed and 
1ml of hydrochloric acid and isopropanol, in a ratio of 1:25, was added to dissolve the 
formazan crystals and further incubated at 37
o
C for 45 minutes. The optical absorbance of the 
solution was measured at 650nm using a microplate reader (Promega, UK). The absorbance 
was converted to cell number, determined from a calibration of different known cell numbers, 
assayed with the MTT assay as described.  
3.2.4 Calcein-AM and Propidium Iodide staining 
Calcein acetoxymethylester (Calcein-AM) is highly lipid soluble and rapidly penetrates the 
plasma membrane of the cells. Initially it is not fluorescent, however, when the ester bonds 
are cleaved by the intracellular esterases of viable cells it becomes hydrophilic and emits a 
green fluorescence indicative of live cells (Kaneshiro et al. 1993). 
Propidium Iodide (PI) is a membrane impermeant and does not penetrate through the 
membrane of viable cells, instead enter the cells via damaged membranes. It binds to the 
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DNA double helix and emits a red fluorescence and is used to identify dead cells in a cell 
population. Both Calcein-AM and PI are excited at 490nm and therefore can be viewed 
simultaneously using a fluorescence microscope.  
50µg/mL stock solution was prepared in DMSO, PI (Invitrogen, Paisley, UK) was diluted in 
water, at a concentration of 100µg/ml. 7µL of Calcein-AM and 25µL of PI were added to the 
cultures and left for 5 minutes in the dark. The stained cultures were observed using a 
fluorescence microscope fitted with a mercury lamp (Carl Zeiss Ltd, Hertfordshire, UK) at a 
magnification of X20. Images of live and dead cells were taken using a digital camera 
(Powershot G5, Canon UK Ltd, Surrey, UK) attached to a light microscope (Carl Zeiss Ltd, 
Hertfordshire, UK).  
3.2.5 Trypan Blue assay 
Trypan blue is derived from toluidine and is also referred to as the dye exclusion method, 
whereby it passes through by the damaged membrane of the cells, staining them blue.  The 
viable cells exclude the dye leaving them white. In order to determine cell viability and cell 
number, a Neubauer haemocytometer (Beckman Coulter Ltd, UK) was used. Trypsinised cells 
were suspended in a small amount of culture medium and mixed with 0.2% w/v solution of 
trypan blue (Sigma, UK) in a ratio of 1:1. The haemocytometer was viewed using a light 
microscope and the number of blue (dead cells) and white cells (live cells) were counted. The 
approximate number of viable cells present was calculated using equation 3.1; 
Cells/ml = Number of white cells x multiplication factor (2000) x dilution factor (2) 
Equation 3-1 
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3.2.6 Von Kossa assay 
The formation of mineralised nodules in osteoblastic-like cells can be assessed using the Von 
Kossa histochemical assay. This method is based on the binding of silver ions to the anions of 
calcium salts such as phosphates. The presence of phosphate ions therefore reduces the silver 
ions to form dark brown or black metallic silver staining in the presence of light illumination, 
indicating mineralised nodules in cell monolayers or tissues (Wang et al. 2006) 
Cell cultures for analysis were washed with PBS and fixed with 10% (v/v) paraformaldehyde 
for 30 minutes. The cultures were serially dehydrated in 70%, 95% and 100% ethanol and air 
dried. 2% (v/v) silver nitrate solution was added and the samples were exposed to UV light 
for 45 minutes. The samples were further rinsed with distilled water and sodium thiosulphate 
(5% v/v) was added to the cultures and left to stand for 2 minutes. The samples were then 
rinsed twice with distilled water and 95% ethanol and left to dry for image analysis 
(Bonewald et al. 2003). Digital images were captured using an inverted light microscope with 
a digital camera attached (CETI, Medline Scientific Limited, UK), for quantitative analysis 
the % area of mineralisation was determined using the image processing and analysis software 
ImageJ 1.43 (National Institutes of Health, USA). 
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3.2.7 Alizarin Red S staining  
Alizarin Red S or 1,2-dihydroxyanthraquinone is a histochemical assay, used to evaluate 
calcium deposits in cells in culture. Alizarin Red S has an affinity for calcium and upon 
binding to calcium gives a red/orange stain.  
40mM Alizarin Red S (Sigma Aldrich, UK) was prepared and adjusted to pH 4.2 with 
10%(v/v) ammonium hydroxide (Fischer Scientific, UK). The cultures were fixed with 10% 
(v/v) paraformaldehyde for 30 minutes at room temperature and washed with PBS. Alizarin 
Red S stain was added to the cultures and left in room temperature for 20 minutes. Excess 
stain was removed and the cultures were washed with PBS. The stained monolayers were 
visualised using an inverted light microscope (Zeiss, UK) and images were captured using a 
digital camera (Canon F2.0, UK). For quantitative analysis the % area of mineralisation was 
determined using the image processing and analysis software ImageJ 1.43 (National Institutes 
of Health, USA). 
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3.2.8 Reverse-transcription polymerase chain reaction (RT-PCR) 
Total cellular RNA was isolated from rat BMSC cells following incubation with 0, 5 and 
20µg/ml of orthosilicic acid (source: sodium metasilicate) for 3, 7 and 10 days.   
RNA isolation was carried out following manufacturer instructions in the Rneasy Kit (Qiagen, 
UK), briefly, the cell monolayers were lysed with beta-mercaptoethanol, a reducing agent 
used for nuclease inhibition, prepared in RLT buffer at a 1/100 (v/v) ratio. Contaminating 
DNA was removed using DNAse. mRNA was quantified and evaluated using a 
spectrophotometer (BioPhotometer, Eppendorf, UK) and by electrophoresis. Electrophoresis 
was carried out on an agarose gel (1% w/v), prepared by dissolving agarose in Tris Acetate 
EDTA (TAE) buffer. For the visualisation of the bands on the gel when exposed to 
fluorescent light, SYBR gold (Invitrogen, UK) a stain used for RNA gels was added to the 
agarose/Tris acetate mixture prior to setting. The agarose gel was poured into a mould and the 
combs used to create the wells were placed in the gel and was allowed to set for 25 minutes at 
room temperature until solidified. The gel was immersed in TAE buffer in an electrophoresis 
tank and the gel loaded with the RNA samples as well as the HyperLadder IV (Bioline, UK), 
which provides the molecular weight markers. The gel was run for approximately 30min at 
120 volts.  
Reverse transcription of mRNA to complementary DNA (cDNA) was carried out using the 
omniscript DNase kit (Qiagen, UK), using Oligo dT primer (0.5µg/ml) and DNase inhibitor 
(40units/µL) from Promega (UK). Concentration of the cDNA was carried out using micron 
filters (Millipore, UK). Samples were prepared for PCR with the addition of REDTaq
®
 
ReadyMix
TM  
mastermix
 
consisting of 12.5µl of REDTaq®, 2µl of forward and reverse primer 
mix, 1µl of template DNA and 9.5µl of RNAse free water per sample.  PCR was carried out 
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using a Mastercycler thermal cycler (Eppendorf, UK) and typical cycling conditions were as 
follows; 94
o
C for 5 minutes, followed by 30 cycles consisting of 94
o
C for 20 seconds for 
denaturing the template, 60
o
C for 20 seconds to anneal the primers and 72
o
C for 20 seconds to 
polymerise the DNA. Finally, the samples were incubated at 70
o
C for 10 minutes and the 
temperature was held at 4
o
C after completion. The primers used are listed in Table 3.1. 
Following PCR the products were electrophoresed in 1.5% (w/v) agarose gels (described 
earlier) and visualised by ethidium bromide staining (3µL from the stock solution, 10mg/ml). 
All samples were kept on ice throughout the experiment.  
Band intensities were quantified using Genesnap/Genetool (Syngene,UK). Band intensities 
for each studied gene were normalised against the house keeping gene glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) for each time point and concentration. These normalised 
cDNA intensities were converted to relative transcription levels using equation 3.2.   
 
 
Equation 3-2 
 
 
 
 
 
 
Relative transcription = Sample normalised cDNA intensity  
 
 
 
Normalised cDNA intensity of 
untreated sample at day 3  
 X 100  
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Table 3.1: Primers used for RT-PCR 
Primer Primer – Full name Sequence of Primers 
Forward (F) Reverse (R) 
Product 
Length 
(bps) 
 
rGAPDH 
 
Glyceraldehyde - 3  
Phosphate 
Dehydrogenase 
 
F- CGA TCC CGC TAA CAT CAA AT  
R- GGA TGC AGG GAT GAT GTT CT 
 
227 
 
rOcalcin 
 
 
Osteocalcin 
 
 
F- TCC GCT AGC TCG TCA CAA TTG G  
R- CCT GAC TGC ATT CTG CCT CTC T 
 
215 
 
 
rOpontin 
 
 
Osteopontin 
 
F- AAG CCT GAC CCA TCT CAG AA  
R- GCA ACT GGG ATG ACC TTG AT 
 
445 
 
rAlkPhos 
 
 
Alkaline Phosphatase 
 
 
F- CTC CGG ATC CTG ACA AAG AA  
R- ACG TGG GGG ATG TAG TTC TG 
 
499 
 
rColl-1α 
 
Collagen Type 1  
 
F – AAA AGG GTC ATC GTG GCT TC 
R – ACT CTG CGC TCT TCC ACT CA 
 
336 
 
rPCNA 
 
Proliferating Cell 
Nuclear Antigen 
 
F- TTG  GAA TCC CAG AAC AGG AG  
R- CGA TCT TGG GAG CCA AAT AA 
 
389 
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3.2.9 Extraction of Type 1 Collagen 
Type 1 collagen was extracted from Wistar rat tail tendons and processed in 0.5M acetic acid 
solution for 48 hours at 4
o
C. Dialysis tubes were prepared by simmering in ethanol (50% v/v) 
for 1 hour and for another hour in a 10mM sodium bicarbonate (NaHCO3) / 1mM EDTA 
solution. The dialysis tubes were further simmered for 1h in distilled water and stored at 4
o
C 
until required. The extracted rat tail tendons were sterile filtered and poured into the dialysis 
tubes and dialysed against 0.1x DMEM for 24h at 4
o
C. The solution was centrifuged at 
10,000 rpm for 24h at 6
o
C (Beckman Coulter, UK), and transferred into glass bottles and 
stored at 4
o
C. The autoclaved glass-ware was used throughout the experiments.  
3.2.10  Collagen fibrillogenesis (turbidity experiments) 
Kinetic analysis of collagen fibril formation was examined in the presence of different 
concentrations of sodium metasilicate, by carrying out studies of the turbidity of the gelling 
collagen (loss of transparency) over a period of time.  
Prior to forming the gel, all solutions were placed on ice. 0.3% (w/v) collagen gels were 
prepared with 10X DMEM and 0.4M sodium hydroxide (NaOH) at a 2:1 ratio. Various 
concentrations of sodium metasilicate were added to the gel solution.  1/1000 (v/v) acetic acid 
was added to make up the desired volume and concentration of the gel. The pH was adjusted 
with 1M NaOH to 8.0-8.5. Phenol red present in the DMEM solution was used as a pH 
indicator, which turns pink between pH 8.0 – 8.5. 1ml of the solution was quickly added into 
a cuvette (1cm) and placed in a UV-VIS spectrophotometer (Cecil Instruments, UK) and the 
absorbance was set at 553nm. The kinetics study was started immediately (t= 0min) and the 
temperature was maintained at 37
o
C and a turbidity-time profile was determined. Turbidity 
experiments were carried out in triplicate to ensure good reproducibility.  
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3.2.11  Atomic Force Microscopy to determine collagen self-assembly 
The atomic force microscope (AFM) allows for the direct measurement of intermolecular 
forces with atomic-resolution characteristics. It has often been used in place of other 
conventional microscopes such as the scanning electron microscope (SEM) and transmission 
electron microscopy (TEM) as it has many advantages in imaging from the nano-scale to the 
molecular scale. It is used when analysing various materials, such as the homogeneity of 
polymers, glasses and composition changes in ceramics as well as imaging biological 
macromolecule interactions.  
A typical AFM system consists of a micro-mechanical cantilever probe and a sharp tip 
mounted onto a piezoelectric scanner and a sensitive photo-detector for receiving a laser beam 
to provide cantilever deflection feedback illustrated in figure 3.1. The AFM probes the sample 
with a sharp tip, usually made of silicon, and makes measurements in 3 dimensions (x,y and 
z), normal to the sample surface.  
The principle of AFM is to scan the tip over the sample surface with feedback mechanisms 
which allow the piezoelectric scanner to maintain the tip at a constant force or height above 
the sample. AFM relies on the forces between the tip and sample and is measured by Hooke’s 
law (equation 3-2) whereby F is the force, k is the stiffness of the cantilever and z is the 
deflections of the lever. 
F= -kz 
Equation 3-3 
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Typical forces between probing tip and sampling range from 10
-11
 to 10
-6
N. AFM can be 
operated in various modes for example, contact mode, intermittent contact mode and phase 
imagings are a few. For the analysis of collagen fibres, the intermittent contact was operated, 
this is whereby the stiff lever is oscillated close to the sample and the tip intermittently 
touches the surface of the sample (Jalili & Laxminarayana 2004).    
 
Figure 3.1: Schematic diagram illustrating the functioning of an AFM. A laser beam from 
the deflection sensor is focussed on the back of the cantilever which deflects and the signal 
changes to an electric signal (Jalili & Laxminarayana 2004). 
Collagen gels were prepared as described in section 3.2.10, with different concentrations of 
OSA and before gelling the sample was swabbed onto clean silicon substrates. The sample 
was left to air dry for 20 minutes and rinsed three times in distilled water to remove any 
excess salts.   
Surface morphology was determined using a NanoWizard II atomic force microscope (JPK 
Instruments, UK) operating in intermittent contact mode at a tip velocity of 2 μm/s, 
employing pyramidal tipped Si cantilevers (PPP-NCL, Windsor Scientific, UK).  
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3.3 Results 
3.3.1 Determining the maximum concentration of OSA without cell death 
Initial studies were carried out to determine the optimum concentration of OSA needed before 
MC-3T3 cell death. MC-3T3 viability was determined by MTT and calcein AM assays, 
Figure 3.2 shows the cell viability of MC-3T3 osteoblasts  doped with 0 – 1.5mg/ml of OSA 
using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. The 
cells were analysed after 72h of incubation and it can be seen the cell viability decreased 
when the concentration of OSA was 0.2mg/ml and further decreased as the concentration of 
OSA increased. There was no difference however, in the high concentrations of OSA and cell 
viability.  
 
Figure 3.2: Viability of MC-3T3 osteoblasts cultured in media containing 0-1.5mg/ml OSA for 
72H, shows that viability decreased when the concentration of OSA increased.  
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It was also noted the colour of the supplemented DMEM changed from orange to yellow as 
the concentrations of OSA increased, indicating that the environment was too acidic for the 
cells to survive (Figure 3.3). 
 
Figure 3.3: Indicates the colour of supplemented DMEM with increasing concentrations of 
OSA from 0-1.5mg/ml. 
Osteoblasts cultured in lower concentrations of OSA, that is, between 0-20µg/ml showed an 
increase in cell viability. This too was determined using the MTT assay (Figure 3.4) as well as 
Calcein AM and Propidium Iodide staining to examine cell viability (Figure 3.5) 
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Figure 3.4: MC-3T3 viability assessed in the presence of 0-20µg/ml OSA for 72H, indicates 
that MC-3T3 cell viability significantly increased (p<0.05) in the presence of 5µg/ml of OSA, 
however viability decreased as the OSA concentration is increased above 15µg/ml, this was 
determined using the MTT assay.  
MC-3T3 cell survival relied on the concentration of OSA, it was noted that concentrations of 
OSA below 5µg/ml showed an increase in cell number (Figure 3.4). Cells cultured without 
OSA showed a cell count of 14x10
4
 after 72h whereas there were approximately 21x10
4
 cells 
in the presence of 5µg/ml of OSA. Cell number decreased, to 13x10
4 
and 6x10
4 
however, 
when the concentration of OSA was increased for 15µg/ml and 20µg/ml of OSA, 
respectively. 
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Figure 3.5: Live/dead fluorescent images of MC-3T3 cells doped with 0-20µg/ml of OSA 
using the Calcein AM (green) and Propidium Iodide (red) assays. Images indicated that 
high concentrations of OSA decreased cell viability. Scale bar denotes 10µm.  
Live/dead fluorescent images show the viability of MC-3T3 cells for 3, 7 and 10 days when 
doped with 0, 5 and 20µg/ml of OSA (Figure 3.5). A decrease in the number of live cells was 
seen over the 10 days with cells cultured with 20µg/ml OSA. Cells with no OSA and 5µg/ml 
OSA illustrated more live cells (green staining) than dead cells (red staining) and the reached 
confluency over the 10 day period.   
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Figure 3.6: 14 day growth curve for MC-3T3 cells doped with various concentrations of OSA, 
indicating that cell number was significantly increased (p<0.05) in the presence of 5µg/ml 
OSA when compared to cells doped with no OSA and with 20µg/ml. This was determined 
using the Trypan blue assay.  
A growth curve was determined to identify the effect of OSA on the attachment and 
proliferation of MC-3T3-E1 cells with time. Cell viability was significantly (p<0.05) higher 
when cells were treated with 5µg/ml OSA on day 7 and 10, when compared with untreated 
cells. Cells cultured with 20µg/ml of OSA showed a decrease in cell number, where only 
1.9x10
6
 cells were viable on day 10 (Figure 3.6). At day 14, however, there was a decrease in 
cell number when cells were treated with 5µg/ml and 20µg/ml OSA concentration as well as 
the untreated samples. This could be attributed to the cells reaching 100% confluency at this 
time point and reducing the surface area for further cells proliferation.  
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3.3.2 Determining mineralisation in the presence of OSA 
The quantification of inorganic phosphate and calcium were examined using Von Kossa and 
Alizarin Red respectively. The stains were used to examine mineralisation in vitro of cells 
doped with various concentrations of OSA only. Cells were not cultured in the presence of 
osteogenic mediators, so as to evaluate the effect of OSA on mineralisation. 
 
Figure 3.7: Deposition of inorganic phosphate when cells are doped with 5ug/ml and 
20ug/ml of OSA over time. Scale bars denote 50µm. 
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The deposition of inorganic phosphate was determined in vitro using the Von Kossa assay. It 
was seen that there was the least phosphate deposition, when cells were doped with 20µg/ml 
of OSA (Figure 3.7). The decrease in phosphate deposition suggests mineralisation is 
concentration dependent and this agrees with the cell viability results whereby there is a 
decrease in cell number when cells are exposed to high concentrations of OSA.  
 
Figure 3.8: Quantitative analysis of phosphate deposits determined with the Von Kossa 
assay, the % area of mineralisation was measured using the software ImageJ. 
Phosphate deposition significantly increased (p<0.05) when cells were treated with 5µg/ml of 
OSA. The % area of mineralisation is 63% and 68% on both day 7 and 10, respectively, when 
compared to cells cultured without OSA where on day 7 the % area of mineralisation is 55% 
and 60.8% on day 10 (Figure 3.8).  
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Figure 3.9: The effect of 0, 5 and 20µg/ml orthosilicic acid on calcium deposition in MC-3T3 
cells. Calcium deposition was determined with the Alizarin Red S stain, Scale bars denote 
200µm.  
Cultures treated with 0, 5 and 20µg/ml of OSA, were stained with alizarin red and indicated 
the presence of mineralised nodules. Cultures treated with no OSA and 5µg/ml of OSA 
showed the presence of calcium deposits over 10 days in osteoblast like cells, however cells 
treated with 20µg/ml OSA did not demonstrate calcium deposition, illustrated in Figure 3.9.  
Quantitative analysis was carried out to determine the actual amount of calcium present in the 
cell cultures when treated with orthosilicic acid (Figure 3.10).  
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Figure 3.10: Quantifying the calcium deposits in MC-3T3 cells cultured with 0, 5 and 
20µg/ml of OSA. Each result is the mean of three observations. Error bars represent 
standard deviations. The % area of mineralisation was measured using the software ImageJ. 
Results that a significantly different (p<0.05) are marked with an asterisk (*).  
Initially, there is little increase in the deposition of calcium for both the non-treated and 
treated samples. There is no significant difference (p>0.05) in the amount of calcium 
determined in the cells cultured without OSA and those treated with 5µg/ml on day 7. There 
is a decrease, however, in the amount of calcium present when cells are treated with 20µg/ml 
of OSA on day 7, when compared to the non-treated cultures (Figure 3.10).  
Osteoblasts treated with the highest concentration of OSA, that is, 20µg/ml show significantly 
less calcium deposition on day 10 however this could be caused by the accumulated 
concentration of OSA, as fresh culture media containing 20µg/ml of OSA was added over the 
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time of the investigation. This is interesting that the presence of low concentrations of OSA, 
may aid in the initiating of nodule formation however if the concentration of OSA continues 
to increase this can inhibit nodule formation and therefore decrease the deposition of calcium. 
It is noteworthy however, that this investigation was carried out when cells were cultured 
without osteogenic media, hence showing the direct effect of OSA on calcium deposition 
without the presence of osteogenic promoters. Finally a decrease in calcium deposition, from 
both the concentrations of OSA, that is, 5 and 20µg/ml on day 10 further elucidates the point 
that the effect of OSA on mineralisation in osteoblast cells is certainly dose dependent.     
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3.3.3 RT-PCR analysis 
The expression of proliferating cell nuclear antigen (PCNA), and osteogenic markers; 
osteopontin, alkaline phosphatase (ALP), osteocalcin and collagen type 1 (COLL-1) were 
quantified in the rat bone marrow cells (rBMCs). Which were induced to proliferate in vitro, 
in the presence of 0, 5 and 20µg/mL of OSA, cultured with or without the presence of 
osteogenic mediators (OM), Ascorbic acid (AA, 200mM), Dexamethasone (Dex, 10
-7
M) and 
β- Glycerophosphate (β-GP, 10mM).  
Ascorbic acid, Dexamethasone and β- Glycerophosphate have shown to promote the 
expression of the osteoblastic phenotype in most bone cells. A series of experiments were 
carried out to evaluate the direct effect of OSA on rBMCs mineralisation as well as its effect 
in synergy with the osteogenic mediators. This was done so as to elucidate the pathway in 
which OSA contributes to cell mineralisation.  
3.3.3.1 Expression of proliferating cell nuclear antigen (PCNA) 
Proliferating cell nuclear antigen (PCNA) is a protein associated with the cell cycle. It is 
known to interact with many components of the cells replication and signalling machinery. In 
this case the expression of PCNA was used to determine the rate of proliferation in rBMCs 
cultured in s-DMEM and treated with orthosilicic acid.   
Visual representation for the expression of PCNA was evaluated when rBMCs were cultured 
without (Figure 3.11) and with (Figure 3.12) the osteogenic mediators, ascorbic acid, β-
glycerophosphate and dexamethasone. All images presented are from one gel image for 
reliable comparison.  
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Figure 3.11: RT-PCR analysis of GAPDH and PCNA expression by rBMCs following 
incubation with 0, 5 and 20ug/ml of OSA for 10 days. Transcription of genes was analysed 
without the presence of osteogenic mediators (OM).  
 
Figure 3.12: RT-PCR analysis of GAPDH and PCNA expression of rBMCs cultured with 
osteogenic mediators and treated with orthosilicic acid.  
Semi-quantitative analysis was determined according to the band intensity and relative PCNA 
expression was determined after being normalised against the house keeping gene, GAPDH.  
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Figure 3.13: Relative transcription (%) of PCNA normalised against the housekeeping gene 
GAPDH. rBMCs were cultured without OM and doped with 0, 5 and 20ug/ml. The error 
bars represent the standard deviation of the mean.  
 
Figure 3.14: Relative transcription of PCNA normalised against the housekeeping gene 
GAPDH. Rat BMCs were cultured with OM and treated with various concentrations of OSA. 
The error bars represent the standard deviation of the mean. 
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Cells cultured without AA, β-GP and Dex, showed little significant change in the expression 
of PCNA when cells were treated with and without OSA (Figure 3.13). The relative 
transcription  for the control and 5µg/ml OSA was 100% and 98% respectively on day 3, 
indicating that OSA had little effect in PCNA expression at this time point. There was a 
decrease in the expression of PCNA expression on day 7 from when cells were treated with 
5µg/ml and 20µg/ml OSA when compared to non-treated samples.  PCNA expression 
increased by day 10 for osteoblasts treated with 5µg/ml of OSA. The relative transcription for 
the control sample was approximately 97% and 102% in cells treated with 5µg/ml. 
Throughout the 10 day period cells doped with 20µg/ml showed a reduction in PCNA 
expression (Figure 3.13). Thus indicating, high concentrations of OSA reduce the 
transcription of PCNA, a protein which is synthesised during the S-phase of the cell cycle and 
is found in the nucleus of dividing cells. These results corroborate with those obtained from 
the viability tests (Figure 3.5)      
Cells cultured with osteogenic mediators and 5µg/ml of OSA showed an approximately 10% 
decrease in the relative PCNA expression when compared to the control on day 3 and a 19% 
decrease on day 7. Cells treated with the highest concentration of OSA showed little change 
or a decrease in PCNA expression throughout the 10 day period when compared to the 
control. This could be attributed to the presence of dexamethasone, a glucocoticoid, which has 
shown to reduce cell proliferation and stimulates differentiation of the rBMCs towards the 
osteogenic lineage. 
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3.3.3.2 Expression of osteopontin, alkaline phosphatase, osteocalcin and collagen 
type1  
 
Figure 3.15: RT-PCR of mRNA expression of the house keeping gene GAPDH,  osteopontin, 
alkaline phosphatase, osteocalcin and collagen type 1 in  rBMCs when cultured without OM 
and treated with OSA at 0, 5 and 20µg/ml for 10 days.  
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Figure 3.16: RT-PCR analysis of GAPDH, Osteopontin, Alkaline phosphatase, Osteocalcin 
and Collagen type 1, after rBMCs were treated with osteogenic mediators and 0, 5 and 
20µg/ml of OSA for 10 days.  
Visual examination of the gels in Figure 3.15 and 3.16 show the expression of osteopontin, 
alkaline phosphatase, osteocalcin and collagen type 1, when cells are treated without OM and 
with OM respectively. The relative transcription of all the osteogenic primers was determined 
according to band intensity and normalised against the house keeping gene, GAPDH.  
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3.3.3.3 Relative osteopontin transcription 
 
 
Figure 3.17: RT-PCR analyses of osteopontin expression after rBMCs were cultured without 
OM (a) and with OM (b) as well as being treated with OSA. Error bars represent the 
standard deviation of the mean. 
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Osteopontin is mostly involved in the regulation of bone resorption as it has shown to 
promote osteoclast differentiation (Rosenthal et al. 2007) and acts as a potent inhibitor of HA, 
therefore inhibiting the mineralisation process (Standal et al. 2004). The relative osteopontin 
expression in rBMCs showed to have no significant effect when treated with the low 
concentration, 5µg/ml, when compared to the control sample. The relative transcription at day 
7 for the non-treated sample was 127% and 129% for the cells treated with 5µg/ml OSA. 
When cells were treated with 20µg/ml OSA, however, relative OPN transcription reduced 
over the 10 day when compared to the cells treated with 5µg/ml or without OSA (Figure 
3.17a).    
In the presence of osteogenic media, the cells stop proliferating and differentiation of cells is 
enhanced. Osteopontin also contains the Arg-Gly-Asp (RGD) sequence which acts as a cell 
binding motif which allows for adhesion molecules to bind to the surface of the extracellular 
matrix.  Therefore, it has previously been suggested that osteopontin may have a role in the 
attachment of bone cells to the matrix (Roach 1994) and thus leading to an increase in OPN 
levels prior to bone mineralisation and as seen in Figure 3.17 b. OPN levels further increase in 
the osteogenic mediators as well as in the presence of OSA. When rBMCs were doped with 
5µg/ml OSA on day 3 a 57% increase was seen when compared to the control, and cells 
doped with 20µg/ml showed approximately 53% increase on the same day. On day 7, the cells 
treated with 5µg/ml showed a 26% increase in osteopontin expression and cells with 20µg/ml 
showed an approximately 14% increase in expression when compared to the control. Overall, 
samples treated with OSA showed to have a significant effect on osteopontin transcription 
during the 10 day study, when compared to the control. A similar trend was seen on day 10, 
whereby samples treated with 5µg/ml showed a 40% increase in OPN transcription and a 
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significant increase of 80% were seen in samples treated with 20µg/ml OSA, when compared 
to the control (Figure 3.17b).   
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3.3.3.4 Relative alkaline phosphatase transcription 
 
 
Figure 3.18: Relative alkaline phosphate transcription (%) of rBMCs cells treated with OSA, 
cultured without OM (a) and with OM (b). The error bars represent the standard deviation 
of the mean.  
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Alkaline phosphatase expression is known to increase during osteogenic differentiation and 
decreases during the formation and mineralisation of the extracellular matrix. Cells treated 
without osteogenic mediators and with OSA showed a decrease in ALP expression over the 
10 day period, that is, ALP expression decreased from 100% on day 3 to 72% on day 7 and 
remained at approximately 75% on day 10. ALP expression increased however, from 76% on 
day 3 to 95% on day 10 when cells were treated with 5µg/ml OSA. When cells were treated 
with the high concentration of OSA, ALP expression decreased by 20% when compared to 
samples treated with 5µg/ml OSA. This further decreased to 49% on day 10, noticeably less 
when compared to the non-treated samples and those samples treated with 5µg/ml OSA 
(Figure 3.18a).   
Osteogenically induced cells treated with orthosilicic acid showed an increase in ALP 
expression on day 3, that is, cells treated with 5µg/ml OSA showed nearly a two fold increase 
in ALP expression, when compared to the control, a similar trend was seen in cells when 
treated with 20µg/ml OSA. These results suggest that the high concentration of OSA does not 
influence ALP expression in the presence of osteogenic mediators, instead may act in synergy 
to promote osteogenic differentiation of the rBMSCs (Figure 13.8b). High concentrations of 
OSA, on the other hand, show a decrease in the expression of ALP without the presence of 
osteogenic mediators, indicating that orthosilicic acid on its own may aid in the formation and 
mineralisation of the extracellular matrix. 
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3.3.3.5 Relative osteocalcin transcription  
 
 
Figure 3.19: Relative osteocalcin transcription (%) of rBMCs cells treated OSA, cultured 
without OM (a) and with OM (b). The error bars represent the standard deviation of the 
mean. 
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Osteocalcin a non-collagenous protein is secreted by osteoblasts and plays a vital role in the 
body’s metabolic regulation as well acting as a marker for early bone mineralisation (Neve et 
al. 2011). Rat BMSCs treated without OSA remained at an average of 120% in osteocalcin 
expression throughout the 10 day period. A similar trend was observed in the relative 
expression for rBMSC treated with 5µg/ml during the 10 day treatment, at approximately 
98%. Cells have shown to have a higher expression of osteocalcin when doped with 20µg/ml, 
that is, 116% on day 7 and 110% at day 10, whereas cells treated with 5µg/ml osteocalcin 
expression remained at approximately 100% over the same time period. This suggests that 
OSA on its own when compared to the osteocalcin expressions obtained from the non-treated 
samples may have little effect on early bone mineralisation, however may still have an effect 
in conjunction with osteogenic mediators (Figure 3.19a).  
The addition of ascorbic acid, β-GP and dexamethasone to the cells, enhanced the relative 
expression of osteocalcin by day 10 with 5µg/ml of OSA. Initially on day 3 and 7 osteocalcin 
expression remained at approximately 120% on both days, when doped with 5µg/ml OSA and 
increased to 161% at day 10. Non-treated samples expressed 100% of osteocalcin on day 3 
and approximately 140% for both days 7 and 10. Indicating there was little up-regulation of 
osteocalcin without the presence of OSA. A noticeable increase was seen with 5µg/ml OSA 
where the expression remained approximately the same for day 3 and 7 at 120% and increased 
to approximately 161% on day 10, nearly 27% more than the control.    
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3.3.3.6 Relative Collagen transcription 
 
 
Figure 3.20: Relative collagen type 1 transcription (%) of rBMCs treated with OSA, cultured 
without OM (a) and with OM (b). The error bars represent the standard deviation of the 
mean.  
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Type 1 collagen is a dominant fibrous protein not only in connective tissues but also present 
in the hard tissues such as bone, and dentine (Viguet-Carrin et al. 2006). It is also present in 
the mineralising cartilage of the epiphyseal growth plates. Collagen is predominantly present 
in the form of elongated fibres known as fibrils, which provide structural strength within 
tissues and form a framework within which other components of the extracellular matrix can 
interact (Landis et al. 2006). Orthosilicic acid treated cells had a significant increase in the 
expression of collagen type 1. 5µg/ml treated cells expressed up to 18% and 22% more 
collagen on days 7 and 10 respectively when compared against the control cultures. This 
increase in transcription indicated that orthosilicic acid on its own, that is, without the 
presence of osteogenic mediators played a fundamental role in matrix formation leading to 
early bone matrix synthesis. A decreasing trend was noticed when cells were doped with the 
highest concentration of orthosilicic acid similar to the expression of osteopontin and alkaline 
phosphatase when cells were cultured without osteogenic mediators (Figure 3.20a).  
Figure 3.20b, indicated that collagen type 1 expression is comparable to the expression 
obtained when cells were cultured without osteogenic mediators and with osteogenic 
mediators. There is an overall increase in the relative transcription of collagen when cells are 
treated with 5µg/ml OSA when compared to the control.  Little difference was seen in cells 
treated with 20µg/ml, when compared to the non-treated cultures, on day s 7 and 10. This 
indicates that orthosilicic acid concentrations play a vital role in collagen type 1 expression, 
therefore an important role the early mineralisation of osteoblast-like cells as well as a 
fundamental role in initial bone formation (Figure 3.20b). To further investigate the role of 
orthosilicic acid on bone modelling, the mechanism of collagen fibrillogenesis was evaluated 
in the presence of orthosilicic acid. 
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3.3.4   Effect of orthosilicic acid on collagen fibrillogenesis in vitro 
Collagen is the most common protein in the organic scaffold of mineralised connective tissues 
and acts as a means for strain energy storage and mechanical support (Heinemann et al. 2011). 
Type 1 collagen has been widely investigated due to its self-organisation properties (Kadler et 
al. 2008). Previously in this chapter it has been shown that the soluble form of silicon, 
orthosilicic acid, augments bone mineralisation, by up-regulating the osteogenic markers, 
osteopontin, osteocalcin as well as type 1 collagen. Hereon interactions between silicon 
species and collagen are investigated via in vitro analysis of the effect of orthosilicic acid in a 
range of different concentrations on collagen fibril formation. These include; turbidity 
profiles, determining the rate of fibril formation, analysing fibril morphology using AFM and 
evaluating the thickness of collagen fibres in various OSA concentrations. 
3.3.4.1 Turbidity profiles  
Type 1 collagen kinetics profiles were determined by carrying out turbidity measurements. 
This measured the rate of assembly of the collagen fibrils as well as the amount of fibrillar 
material formed.  
 
Figure 3.21: A typical turbidity profile of collagen fibrillogenesis (Kuo et al. 2005).  
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Under typical assembly conditions, the absorbance curve is a function of time and with a 
sigmoidal profile (Figure 3.21). In general, there are 3 phases; 
 Lag phase – whereby triple helices undergo a conformational change and little or no 
aggregation occurs, leading to no significant change in turbidity. 
 Growth phase – represents the occurrence of fibril formation, producing nano/micro 
meter fibres and leading to a rapid increase in turbidity. 
 Lateral phase – fibril association leads to gelation which causes the turbidity to reach a 
constant value.  
 
Figure 3.22: Turbidity measurements carried out for 30 minutes, of collagen type 1 fibril 
formation in the presence of increasing concentrations of OSA. Error bars indicate the 
standard deviation of the mean (n=4)  
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Collagen is soluble at a low pH and can be reconstituted to fibrils by neutralisation, for 
example with the addition of sodium hydroxide. The fibril formation is associated with a 
strong increase of the viscosity of the solution and leads to a 3D network of collagen fibrils, 
which exhibit ‘gel-like’ properties.  
Turbidity measurements from Figure 3.22 showed typical sigmoidal curves for the collagen 
gels, with and without orthosilicic acid. The lag phases are comparable, however, the lag 
phases for the control and collagen with 20µg/ml OSA were shorter than the gels synthesised 
with higher concentrations of orthosilicic acid that could not be quantified. Collagen gels with 
50, 100 and 200µg/ml of OSA, showed to have an increase in lag phase as the concentrations 
increased, that is, 1.4 minutes for 50µg/ml , 1.63 minutes for 100µg/ml and approximately 2 
minutes for collagen gels prepared with 200µg/ml OSA. Indicating that OSA increases the 
time needed for the collagen triple helices to undergo conformational change. This 
interaction, however, is highly dependent on the concentration of the silicon source, as in the 
presence of high concentrations of OSA the association of the protein chains is hindered. 
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Figure 3.23: Complete turbidity profiles of the type 1 collagen gels prepares with increasing 
concentrations of OSA.   
During the fibrillogenesis phase sodium silicate modifies the fibrillogenesis process at low 
concentrations.  A rapid increase in turbidity was noticed after the lag phase, signifying the 
formation of the fibres of the collagen gel.  The growth phase of the collagen gels was 
quantified from the turbidity profiles using the following equation:  
tg = tp - tlag 
tg – growth phase 
tp – lateral phase 
tlag – lag phase 
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Collagen gels prepared with orthosilicic acid decreased the growth phase when compared to 
the control. The growth phase decreased as the concentration of OSA increased from 20 – 
100µg/ml, however increased in the presence of 200µg/ml of OSA. The decrease in the 
growth phase indicated that OSA increased the rate of fibril formation (Figure 3.23).     
 
Figure 3.24: Growth time of fibril formation of collagen gels in the presence of various 
concentrations of OSA  
The time needed for fibrils to form decreased significantly in the presence of orthosilicic acid 
(Figure 3.24). Collagen fibrils formed in approximately 10.96 minutes without the presence of 
OSA and this time decreased to approximately 7 minutes when supplemented with 20µg/ml. 
The growth time for fibril to form in the presence of 50µg/ml increased slightly to 8.16 
minutes; however this was still lower when compared to collagen fibril growth produced 
without OSA.  When the concentration of OSA was increased to 100µg/ml and 200µg/ml the 
time required for fibril was significantly higher and increased to 27.23 and 45.5 minutes 
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respectively. Indicating that collagen degradation occurs in the presence of higher 
concentrations of OSA, however the presence of OSA in optimum concentrations between 20-
50µg/ml the rate of fibril formation is increased. This was further investigated by observing 
the morphology of the fibres in the presence of various concentrations of OSA.  
3.3.4.2 Collagen fibril morphology using AFM 
The morphology of the collagen fibres varied depending on the concentration of orthosilicic 
acid. Fibrils with variable diameter sizes were formed at different concentrations of OSA. 
Figure 3.25 illustrates the fibril network in the collagen gels.  
 
Figure 3.25: AFM images of collagen fibres when collagen gels prepared with various 
concentrations of OSA  
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It can be seen that collagen fibrils are a densely packed in the presence of OSA when 
compared to the control. Collagen gels made with 5-50µg/ml of OSA showed a more intricate 
network of fibres when compared to gels made without OSA. The collagen gels made with 
higher concentrations, that is, with 100 and 200µg/ml of OSA led to the degradation of the 
gel, indicating that OSA in lower concentrations modifies the collagen fibril network, 
however, in supra-physiological condition may inhibit fibril formation and collagen gel 
production. This is also evident when determining the growth time for fibril formation, as the 
fibres take longer to form or may not have formed at all in these concentrations. The effect 
OSA on collagen fibre diameter was further determined from the AFM images (Figure 3.26). 
 
Figure 3.26: Diameter of collagen fibres determined in the presence of various 
concentrations of OSA.  
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The presence of OSA in collagen gel formation demonstrated a significant effect in the 
diameter sizes of the fibrils formed. Gels produced with, 5µg/ml OSA, have shown no 
significant effect in the fibril diameter size when compared to the control, that is, the diameter 
was approximately 30.72nm for the collagen gels only and 33.5 ± 3nm for the gels produced 
with 5µg/ml OSA, however, it was noticed that with the presence of 5µg/ml OSA the gels 
formed a more intricate network of fibres and visually, more branching was seen when 
comparing the images to the control collagen sample (Figure 3.25). The diameter size further 
increased to 50.56nm when 20µg/ml of OSA was added, and 81nm in the presence of 
50µg/ml of OSA. In the higher concentration of OSA, that is, between 100-500µg/ml, the 
collagen gels begin to degrade and thinner fibres were formed, and collagen formed a weak 
gel. This illustrates that OSA at lower concentrations, plays a key role in the conformation of 
collagen fibres as well as the branching and the network of the gel in vitro and may play a 
similar role in collagen balance in vivo.  
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3.4 Discussion 
Previously, it has been demonstrated that silicon regulates early bone homeostasis in vivo 
(Carlisle, 1976). In this chapter it has been shown that silicon in its soluble form as 
orthosilicic acid, promotes early bone mineralisation by enhancing the expression of early 
osteogenic markers as well as having a significant effect on collagen type 1 fibrillogenesis.  
The concentration-response relationship of orthosilicic acid on osteoblast cells was 
determined and the optimum concentration for cell survival and mineral deposition was 
evaluated in vitro. In the presence of high concentrations, there is a decrease in cell 
proliferation (Figure 3.6) however in the presence of an appropriate OSA concentration 
(5µg/ml) osteoblast proliferation was promoted. It has been suggested that OSA stimulates the 
entry of cells into the S phase whereby DNA synthesis takes place as well as the G2 phase, the 
gap between DNA synthesis and mitosis, of the cell cycle (Shie et al. 2011). Higher 
concentrations than 5µg/ml of OSA were shown to cause cell death. 
To assess the role of OSA in cell function, the effect on mineralisation was determined. Early 
phosphate and calcium deposition were simultaneously seen in the presence of 5µg/ml 
concentration of OSA (figures 3.7 – 3.10). Cells treated with 20µg/ml OSA showed an 
inhibition of the mineralisation and nodules formation over the 10 day period, as well as cell 
death; this is in agreement with the proliferation studies carried out. The presence of mineral 
deposits indicates that Si in the form of orthosilicic acid initially plays a role in early bone 
mineralisation as well as nodule formation in osteogenic cells.  Higher concentrations of OSA 
have shown to affect the cell cycle and lead to cell death, on the other hand lower 
concentrations of OSA, such as 5µg/ml, can act as a regulating factor for the deposition of 
calcium and phosphates in bone tissue.  
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Rat bone marrow cells were induced to differentiate to the osteogenic lineage in the presence 
of osteogenic mediators; ascorbic acid, β-glycerophosphate and dexamethasone.  The effect of 
OSA was evaluated when rBMCs were cultured with or without the osteogenic mediators and 
the expression of osteogenic markers; osteopontin, alkaline phosphatase, osteocalcin and 
collagen type 1 were evaluated. 
The relative osteopontin expression in rBMCs showed to have no significant effect when 
treated with the low concentration, 5µg/ml, when compared to the control sample. When cells 
were treated with 20µg/ml OSA, however, relative OPN transcription reduced over the 10 day 
when compared to the cells treated with 5µg/ml or without OSA (Figure 3.17a). Osteopontin 
also contains the Arg-Gly-Asp (RGD) sequence which acts as a cell binding motif which 
allows for adhesion molecules to bind to the surface of the extracellular matrix.  Therefore, it 
has previously been suggested that osteopontin may have a role in the attachment of bone 
cells to the matrix (Roach 1994) and thus leading to an increase in OPN levels prior to bone 
mineralisation. OPN levels further increase in the osteogenic mediators as well as in the 
presence of OSA (Figure 3.17b). 
Alkaline phosphatase is an enzyme that is normally present in high concentrations in growing 
bone and is often used as a marker to indicate bone mineral deposition. Orthosilicic acid in 
low concentrations of 5µg/ml increased ALP expression, without cells being osteogenically 
induced after 10 days in culture (Figure 3.18a). Rat BMCs induced with osteogenic mediators 
however, demonstrated a significant effect in ALP expression, this could be attributed to the 
presence of β-glycerophosphate which promotes mineralisation in the differentiated 
osteoblasts as it is rapidly hydrolysed in the presence of alkaline phosphatase within the cell, 
thus producing high levels of phosphate ions and creating an ideal environment for mineral 
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deposition (Rupani et al. 2012). When the cells were osteogenically induced, OSA further 
increased ALP expression, when compared to cells treated without OSA. Anderson et al 
(2008)  suggested that the cells absorb the orthosilicic acid present, which further promote 
nodule formation of the minerals, leading to an increase in ALP expression both in osteogenic 
induced cells (Anderson et al. 1998). 
Although orthosilicic acid has shown to be an essential element in bone formation, with the 
analysis of osteogenic markers such as ALP and Collagen type 1, little evaluation has been 
carried out to determine whether OSA effects early bone mineralisation. RT-PCR analysis on 
osteocalcin expression was carried out as it is an early mineralisation marker for the reason 
that it is a key Ca-binding protein that is exhibited when early mineralisation takes place 
(Varanasi et al. 2011).  Interestingly, when cells are treated with OSA and when no 
osteogenic mediators are present, osteocalcin expression is down regulated, suggesting that, 
high concentrations of OSA on its own may actually be toxic to cells therefore leading to cell 
death (Figure 3.19a). In the presence of osteogenic mediators on the other hand, an up-
regulation of osteocalcin was observed in the presence of 5µg/ml, showing that OSA and 
osteogenic mediators act in synergy to promote early bone formation (Figure 3.19b). The 
presence of ascorbic acid in the osteogenic media is known to aid in the formation of the 
collagen extracellular matrix which is connected to an increase in alkaline phosphatase 
activity and therefore associated in forming the mineralised matrix. The addition of the 
glucocorticoid, dexamethasone induces cell differentiation into the osteogenic lineage, 
therefore indicating an increase in osteocalcin expression when cells were treated with 
osteogenic media.  
An up-regulation of collagen type 1 was observed in cells treated with OSA and without the 
presence of osteogenic mediators (Figure 3.20). These results are in agreement with Reffit et 
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al (2003), whereby, they showed that physiological concentrations of soluble silicon enhance 
the synthesis of collagen type 1 in osteoblastic cells. Collagen is secreted into the extracellular 
space during the hydroxylation of proline residues of the collagen chains, a reaction catalysed 
by prolyl hydroxylase, an enzyme involved in the production of collagen. An increase in 
prolyl hydroxylase activity was observed when Si was added into the diets of Si-deficient 
animals, therefore it has been suggested that Si may affect the rate of synthesis of collagen. 
The up-regulation of collagen is further induced by the presence of ascorbic acid which at the 
same time induces osteocalcin. Since collagen and osteocalcin expression were up-regulated 
in the presence of ascorbic acid, it is possible that Si ions play an integral role in intracellular 
and extracellular pathways in osteogenesis (Varanasi et al. 2011) 
The direct interaction between silicic acid and collagen type 1 was investigated, when a 
significant up-regulation of collagen was seen in the presence of orthosilicic acid. The 
mechanism of collagen self-assembly is entropy driven (Kadler et al. 2008) whereby, there is 
a loss of solvent molecules from the surface of the collagen molecule (Kadler et al. 1996) 
leading to fibril formation.  The presence of low concentrations of orthosilicic acid speeded 
the fibril formation process; however concentrations higher than 100µg/ml inhibited collagen 
self-assembly (Figure 3.25). It has been suggested that orthosilicic acid interacts through 
hydrogen bonding between the specific sites on the protein helices. On the other hand, 
concentrated orthosilicic acid, is mainly constituted of negatively charged poly-silicic acids 
and these interfere with the triple helices assembly via electrostatic interactions (Coradin et al. 
2006). A change in morphology of collagen fibres in the presence of OSA was observed. The 
collagen fibres were thicker and a more intricate network of fibres was formed when OSA 
was added (Figure 3.25). It has been suggested that orthosilicic acid may induce a 
conformation change in collagen maybe by modifying its hydration state through changes in 
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hydrogen bonding between helices and localised water molecules; this slows the process 
down and allows for better packing of the triple helices within the fibres, hence showing a 
compact fibril network. Silicon is also known to cross-link between collagen proteoglycans, 
therefore resulting in the stabilisation of bone matrix molecules and preventing their 
enzymatic degradation (Reffitt et al. 2003). 
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3.5 Conclusion  
The effect of orthosilicic acid was investigated on osteoblast response in vitro. The optimum 
concentration of OSA was determined for cell survival and differentiation. The presence of 
orthosilicic acid in osteoblast like cells, led to the early formation of calcium and phosphate 
nodules, indicating OSA plays a key role in early mineralisation of osteoblast cells. It is 
important to note, however, non-quantifiable silicon was present within the mineral 
composition of the cells.  
RT-PCR analysis showed that OSA induces differentiation in rat bone marrow cells by up-
regulating early osteogenic markers. A significant effect on collagen type 1 expression was 
noted when cells were treated with orthosilicic acid and further investigations were carried out 
to determine the direct interactions between collagen and silicon. 
Collagen fibril formation was altered with the addition of OSA, which formed a compact 
collagen network, illustrating that, the presence of silicon is essential for early bone formation 
and for continuous bone remodelling and healing. 
By determining the optimum concentration for cell survival, will allow for the development of 
silicon-containing biomaterials, which will have a more tailored release of Si(OH)4 and 
therefore creating an ideal environment, for cell survival and differentiation and ultimately 
bone formation.   
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4. Comparing the release of orthosilicic acid from silicate 
containing biomaterials 
4.1 Introduction 
In recent years there has been a great interest in the influence of silicon on the formation of 
biological minerals (Perry & Keeling-Tucker 1998). In the previous chapter it has been shown 
that the soluble form of silicon, orthosilicic acid [Si(OH)4], has a positive impact on bone 
mineralisation. Silicon in its various forms such as silicate (SiO4
4-
), silica, porous silicon and 
orthosilicic acid has been incorporated into biomaterials, for example hydroxyapatite (Patel et 
al. 2002), Bioglass
® 
(Xynos et al. 2000), and calcium phosphate cements (Guo et al. 2007). 
These silicon containing biomaterials have shown to enhance the attachment and proliferation 
of osteoblast-like cells (Heinemann et al. 2011; Bosetti et al. 2003; Ni et al. 2008) There has 
been little systematic investigation, however to determine whether it is the silicon causing 
these positive biological effects from the biomaterial or other materials present within the 
silicon based biomaterial, for example, the release of calcium ions from silicon-substituted 
calcium phosphates. In this chapter, the therapeutic delivery of silicon in the form of 
orthosilicic acid was evaluated, when it is incorporated into PLGA microspheres. 
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4.1.1 Choice of material 
Microspheres have received considerable attention due to their potential importance in the 
area of microencapsulation (Wang et al. 2009). Biodegradable synthetic and natural polymers 
have been used in the fields of orthopaedics (Gunatillake & Adhikari 2003), controlled 
delivery systems (Jain 2000) and reconstructive surgery (Mano et al. 2007). To date, however, 
time and site of the delivery of silicon is still one of the prominent challenges in regenerative 
medicine. Controlled silicon delivery, via silicon based biomaterials, can effectively enhance 
bone mineralisation by reducing the release of high concentrations of silicon at a given time, 
which may cause toxicity within the target site (Shi et al. 2009). Time-controlled delivery can 
be achieved by embedding or encapsulating orthosilicic acid within the polymeric matrix, 
therefore allowing the release of OSA in a manner tailored to a particular application.  
4.1.1.1 Synthetic Polymer - Poly lactic-co-glycolic acid (PLGA) 
Poly lactic-co-glycolic acid (PLGA) has shown potential as a drug delivery vehicle as well as 
a scaffold in tissue engineering (Wischke & Schwendeman 2008). PLGA is a FDA (Food and 
Drug Administration) approved polymer, and it has been widely used as a delivery vehicle for 
drugs (Yunos et al. 2008), proteins (McGinity & O’Donnell 1997) and cells (Chun et al. 
2004). It is often favoured over other biodegradable polymers due to its established uses, 
favourable degradation characteristics as well as possibilities for sustained drug delivery. It 
can be also implanted or injected in the site of interest without the need for major surgical 
procedures (Xue et al 2004).  
PLGA is a co-polymer of poly-lactic acid and poly-glycolic acid, during polymerisation these 
monomers are linked together via ester bonds, yielding a linear aliphatic polyester (Figure 
4.1) (Makadia & Siegel 2011). Many forms of PLGA can be formed with various lactide and 
glycolide ratios, leading to an amorphous material (Gabler et al. 2007).  
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Figure 4.1: Structure of PLGA, whereby X is the number of lactic acid units and Y is the 
number of glycolic acid units (Makadia & Siegel 2011) 
PLGA degrades by the hydrolysis of its ester bonds in the presence of water. It’s 
toxicologically safe by-products; glycolic acid and lactic acid, are broken down to CO2 and 
water by the normal metabolic pathways in the body (Figure 4.2), thus making it suitable for 
use in vivo (Zolnik & Burgess 2007).  
 
Figure 4.2: Hydrolysis of PLGA in the presence of water, yields lactic acid and glycolic acid 
monomers (Makadia & Siegel 2011). 
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4.1.1.2 Calcium silicate cements 
The bioactivity of silicon was first discovered in Bioglass
®
 (Xynos et al. 2000) which has 
been incorporated into various calcium based cements such as β-dicalcium silicate which is 
the most reactive constituent in Portland cements (Guo et al. 2007). Silicate cements are 
mouldable and have been assessed as drug delivery devices. β-dicalcium silicate, for example,  
has many advantageous characteristic when compared to other inorganic cements, such as, 
reduced setting time in vitro and in vivo and increased mechanical properties close to that of 
cortical bone (Wang et al. 2006). Recent studies have shown the β-dicalcium silicate may be 
used as a potential candidate for hard tissue repair, as the release of silicon and calcium from 
the material have shown to enhance osteogenesis. Both the calcium and silicon ions are 
important to nucleation and growth of apatite and influence the biological metabolism of 
osteoblastic cells, leading to mineralisation and bone-bonding (Su et al. 2010). 
In this chapter β-dicalcium silicate was used as an alternative source to sodium metasilicate 
forming a biocomposite with the biodegradable polymer, PLGA. The combining of bioactive 
cements and polymers, has been of great interest in recent years as these biocomposites 
appear to be more beneficial than conventional ceramics or polymer biomaterials alone.  
Here we have compared the release of OSA from PLGA spheres using a soluble form of 
OSA, sodium metasilicate and a sparingly soluble source, β-dicalcium silicate. The 
encapsulation efficiency of orthosilicic acid into these delivery mechanisms was determined 
and the morphology and size distribution was also evaluated. Furthermore MC-3T3 cell 
attachment and proliferation in the presence of calcium silicate cements was examined. The 
overall aim of this work was to exert some control over the release rate and enable controlled 
delivery of OSA from these delivery systems. 
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4.2 Materials and methods 
4.2.1 Synthesis of PLGA microspheres 
All chemicals and reagents were purchased from Sigma-Aldrich (Gillingham, UK), unless 
stated otherwise. 2% (w/w) poly(lactic-co-glycolic acid) (PLGA) 50:50 with acid end groups 
(Lakeshore Biomaterials, Germany) was prepared by dissolving the polymer in 
dichloromethane (DCM)  for 4h at room temperature. 0.5% w/v Poly-vinyl alcohol (PVA) 
solution was prepared in distilled water and stirred for 3h at 200
o
C on a hot plate magnetic 
stirrer (Bibby-B212, UK). The sources of orthosilicic acid were either sodium metasilicate 
nanohydrate (Na2SiO3.9H2O) to form a water/oil/water (w/o/w) emulsion or calcium silicate 
for a solid/oil/water (s/o/w) emulsion.  
4.2.2 Synthesis of β-dicalcium silicate 
The Pechini technique was used for the preparation of calcium silicate powder (Tan et al. 
2010). Whereby, a 2:1 ratio of calcium nitrate tetra-hydrate and colloidal silica were dispersed 
in distilled water separately. 2M citric acid (C2H6O7.H2O) prepared in distilled water was then 
added to the solution. The solution was stirred until clear and 4M ethylene glycol (C6H6O) 
was added to the solution. The mixing solution was placed on a hot-plate stirrer (Heidolph, 
Germany) at 90˚C, overnight, in a fume cupboard to evaporate the excess solvent. The 
resultant white cloudy residue was dried overnight in a furnace (Carbolite-CWF 1300, UK) at 
150˚C. The dried residue was ground to a fine powder and calcined at 800˚C for 3h. 
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4.2.3 Characterisation of β-dicalcium silicate using XRF and XRD 
The calcined powder was characterised by X-ray diffraction (XRD; Bruker, UK) and X-ray 
fluorescence (XRF; Bruker, UK) to determine the phase purity of β-dicalcium silicate and 
elemental composition of the powder respectively.  
4.2.4 Solvent evaporation method 
In the solvent evaporation method, the polymer is dissolved in suitable water immiscible 
solvents such as dichloromethane and water soluble ‘drugs’. In this case the silicon source is 
dissolved in the polymeric solution, the resultant solution is then emulsified in an aqueous 
phase for example PVA to form droplets. For microspheres to form the organic solvent, DCM 
diffuses into the aqueous solvent and evaporates at the water/air interface.    
4.2.4.1 Microsphere production using the w/o/w emulsion technique  
Sodium metasilicate (134mg/ml) as a source of orthosilicic acid, was encapsulated into PLGA 
microspheres using the w1/o/w2 technique illustrated in Figure 4.3a, whereby a 4:1 polymer: 
sodium metasilicate solution (w1/o) was homogenised (IKA
®
, Germany) for 25s at 24,000rpm 
and added into 200ml of 0.5% v/v PVA solution (w2) and stirred continuously at 700rpm for 
3h. After complete evaporation of the solvent (DCM) the microspheres were vacuum filtered 
using a 0.2µM filter paper (Millipore, UK), washed three times with distilled water, to ensure 
any excess DCM was removed, and left to dry at room temperature overnight (Figure 4.3b). 
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Figure 4.3: Schematic diagram illustrating microsphere production (a) and image of 
microspheres after production (b) 
 
 
 
 
 
 
 
a 
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4.2.4.2 Microsphere production using the s/o/w emulsion technique 
Various amounts of β-dicalcium silicate powder (Table 4.1) were encapsulated into PLGA 
microspheres using the solid/oil/water (s/o/w) emulsion technique. A similar technique was 
used as described in Section 4.2.4.1.; however the sodium metasilicate was replaced with 
calcium silicate, hence encapsulation of a solid into the oil phase.  
 
4.2.5 Characterisation of microspheres 
4.2.5.1 Determining the morphology of the microspheres 
The external morphology of the microspheres was examined using a scanning electron 
microscope (SEM), whereby the microspheres were mounted onto a stub and coated with gold 
(EMSCOPE, UK) and viewed using the SEM (Jeol 6060LV, Japan). 
4.2.5.2 Laser diffraction particle size distribution  
The particle size was determined using a Mastersizer2000 (Malvern, UK). The measurements 
were carried out in distilled water, which acted as the background solvent. The samples were 
measured 10 times and the average particle size distribution was determined. 
Table 4.1: Masses of polymer and CaSiO3 used in the fabrication of micro-particles 
 
Sample Amount of polymer (PLGA+DCM) (g) Amount of CaSiO3 (mg) 
A 4.9 100 
B 4.8 200 
C 4.95 50 
D 4.98 20 
E 4.99 10 
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4.2.6 Determining the concentration of OSA – Molybdenum blue method 
For the determination of OSA, the silicomolybdate method showed to be the most suitable as 
it measured the monomeric form of silicon, that is, orthosilicic acid rather than elemental Si. 
The reaction of molybdic acid with Si(OH)4 produced a yellow complex, it is often used when 
the concentration of OSA is higher than 1 part per million (ppm).. The reaction of molybdic 
assay in the presence of OSA is shown in equation 4-1. 
 
 
 
Orthosilicic acid depolymerises slowly and reacts with molybdic acid leading to the formation 
of silicomolybdate thus producing a yellow complex. When the concentration of OSA is only 
a few ppm the absorbance detected by the yellow complex is often insufficient, therefore for 
accurate measurement, the yellow complex is reduced to molybdenum blue using a reducing 
agent, 1-amino-2-naphtol-4-sulphonic acid which increases the sensitivity of analysing OSA 
(Iler 1955).  
The reagents required for the colourimetric assay include; 1N hydrochloric acid (HCl) (Fisher 
Scientific, UK). 100mg/ml ammonium molybdate (Sigma-Aldrich, UK), was prepared in 
distilled water and the pH was adjusted between 7 and 8 with 2M NaOH (Fisher Scientific, 
UK). 100mg/ml of oxalic acid (Fisher Scientific, UK) was prepared in distilled water. The 
reducing agent was prepared by dissolving 500mg of 1-amino-2-naphthol-4-sulfonic acid 
(Sigma-Aldrich, UK), and 1g of sodium sulphate (Sigma-Aldrich, UK) in 500ml of distilled 
water. A second solution made up of 30g of sodium bisulfite (Sigma-Aldrich, UK) was 
7Si(OH)4 + 12H6Mo7O24.4H2O + 126H2O = 7H8Si(Mo2O
7+)6.28H2O 
Equation 4-1 
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dissolved in 150ml of distilled water and the two solutions were mixed, filtered and 
refrigerated to avoid exposure to light.  
Ammonium molybdate reacts with hydrochloric acid to form molybdic acid and ammonium 
chloride (Equation 4-2): 
(NH4)6Mo7O24.4H2O + 6HCl  H6Mo7O24.4H2O + 6NH4Cl 
Equation 4-2 
Molybdic acid also reacts with phosphates yielding phosphomolybdic acid and this can 
interfere in the determination of orthosilicic acid. Oxalic acid was added to remove any 
phosphates if present.  
The concentration of the OSA was determined using the molybdenum blue colourimetric 
assay which includes 60µl of 1M hydrochloric acid (HCl), 120µl of ammonium molybdate 
reagent, 90µl of oxalic acid and 120µl of the reducing agent 1-amino-2-napthol-4-suphonic 
acid (Kortesuo et al. 2000). The absorbance of the solution was determined at 650nm using a 
UV spectrophotometer (Cecil Instruments, UK). 
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4.2.7 Determining the encapsulation efficiency of OSA in the microspheres 
The amount of OSA entrapped within the polymeric matrix was determined by dissolving the 
PLGA microspheres in DCM and distilled water. The mixture was vortexed and left at room 
temperature for 1h. The aqueous phase (water phase), containing the hydrophilic silicon, was 
collected and the concentration of orthosilicic acid was determined using the colourimetric 
method previously described (4.2.6). The encapsulation efficiency (EE) was calculated as the 
ratio of total amount of orthosilicic acid entrapped in the microspheres to total amount of 
orthosilicic acid used in production (Equation 4-3). 
EE (%) = (Mass of OSA determined) / (Mass of OSA added) x 100 
Equation 4-3 
4.2.8 Determining the release of OSA  
To determine the release of OSA from the PLGA microspheres and composites, a known 
mass of microspheres was suspended in 100ml of dissolution medium, in this case distilled 
water, which was placed in a shaker (Gallenkamp, UK) at 150rpm at 37
o
C. 3ml of distilled 
water was taken from the flask at specified time intervals and passed through a 0.22µM filter.  
To maintain a constant volume of the dissolution medium, 3ml of fresh distilled water was 
replaced after each measurement. The concentration of OSA was determined using the 
molybdenum blue colourimetric assay.  
 
 
Chapter 4 
109 
 
4.2.9 Determining the response of MC-3T3-E1 cells to calcium silicate 
composites 
The attachment and proliferation of MC-3T3 cells on the calcium silicate composites was 
determined over 7 days using a blue fluorescent 4’6-diamidino-2-phenylindole (DAPI) 
nucleic stain (Invitrogen, UK).  MC-3T3-E1 cells were seeded onto the surface of the 
composites as described in section 3.2.2. A 5mg/ml DAPI stock solution was prepared 
according to the manufacturer’s instructions (Invitrogen, UK). For the staining of cells, the 
DAPI stock solution was diluted to a concentration of 300nM in PBS. The samples were 
rinsed 3 times in PBS and 2ml of DAPI/PBS stain was added onto the sample and left for 3 
minutes in the dark. The excess stain was removed after 3 minutes and the samples rinsed in 
PBS. The samples were mounted onto a slide and a drop of ProLong Gold antifade 
(Invitrogen, UK) reagent was added and the sample covered with a cover slip. The stained 
samples were observed using a confocal microscope (Leica, UK).  
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4.3 Results 
4.3.1 Incorporation of sodium metasilicate into PLGA microspheres  
In this section the results regarding the release of OSA from microspheres encapsulated with 
sodium metasilicate are described. 
4.3.1.1 Synthesis of micro-particles and encapsulation efficiencies 
A saturated solution of sodium metasilicate at a concentration of 134 mg/ml was used as the 
initial source of OSA.  This concentration was used as it was necessary to encapsulate a high 
concentration of OSA into the PLGA microspheres.  
Various formulations of microspheres were made in order to entrap the maximum amount of 
OSA possible into the PLGA microspheres. This was achieved by changing the experimental 
conditions to increase the encapsulation of OSA without compromising the size and 
morphology of the particles. The encapsulation efficiencies are listed in Table 4.2 in 
accordance with change in formulation of the PLGA microsphere.   
To begin with no change to the sodium metasilicate (134mg/ml) and PVA solutions was 
made, the pH was left at 13.42 for the sodium metasilicate and pH 7 for the PVA solution, 
however when the microspheres were dissolved in DCM and the encapsulation efficiency 
calculated, no OSA was detected within the PLGA microspheres.  
A 0.09% encapsulation efficiency was calculated when the pH of sodium metasilicate was 
changed from pH 13.42 to pH 7 (Experiment 2). Sodium metasilicate is a salt formed by the 
alkali metal Na
+
 and the silicate SiO3
2-
. This silicate is soluble in water and is hydrolysed in 
aqueous yielding orthosilicic acid as shown in equation 4-4 (Iler, 1979). 
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SiO3
2- + 3H2O  Si(OH)4 + 2OH
- 
Equation 4-4 
The pH of sodium metasilicate was therefore adjusted to pH 7 so as to achieve maximum 
encapsulation within the polymeric matrix. Mostly, basic solutions such as sodium 
metasilicate are more soluble in acid and neutral conditions and tend to diffuse into the PVA 
solution (pH 6.78) from the PLGA microspheres leading to low encapsulation efficiencies 
within the microspheres. By decreasing the pH of the sodium metasilicate salt close to neutral 
with hydrochloric acid (HCl), the sodium metasilicate did not diffuse into the larger water 
phase (Experiment 2). 
Table 4.2: The various formulations used to increase encapsulation efficiency of OSA 
 
 
 
Experiment pH of sodium 
metasilicate 
solution 
Continuous phase (large W2 Phase) EE (%) 
1 13.42 PVA 0.5% 0 
2 7 PVA 0.5% 0.09 
3 7 PVA 0.5% saturated with sodium 
metasilicate 
No 
microsphere
s 
4 7 PVA 0.5% saturated with colloidal 
silica pH 6 
0.52 
5 13.42 PVA 0.5% saturated with colloidal 
silica pH 6 
1.19 
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The addition of HCl into sodium metasilicate produced a silica gel, which was encapsulated 
into the PLGA microspheres. The reaction between sodium metasilicate and HCl can be 
represented as (Equation 4-5) (Ruiz-Hitzki et al., 2008); 
NaSiO3 + 2HCl +H2O  Si(OH)4 + 2NaCl 
Equation 4-5 
0.09% is a relatively low encapsulation of sodium metasilicate into PLGA microspheres. This 
could be due to the silicate salt diffusing quickly from a high concentration in the polymer 
solution to a lower concentration in the large water phase (PVA), before the microspheres are 
fully formed.  To reduce this diffusion rate of the metasilicate from the PLGA solution the 
large PVA solution was saturated with sodium metasilicate (experiment 3). The addition of 
sodium metasilicate to the PVA solution changed its pH from 6.78 to 13.57, and as a result no 
microspheres were produced. It has previously been suggested the PLGA degrades in high 
acid and basic condition (Zolnik & Burgess 2007). 
To maintain the same pH of the PVA but saturate the large water phase with silicon, by means 
of reducing diffusion of OSA from the PLGA solution, the source of orthosilicic acid was 
replaced with colloidal silica and the pH was adjusted with sulphuric acid 5% v/v (H2SO4) to 
pH 6.  The encapsulation efficiency further increased to 0.52% (Experiment 4). Indicating that 
by saturating the larger water phase reduces the diffusion of sodium metasilicate into the PVA 
solution, therefore being encapsulated into the PLGA microspheres. By maintaining the pH of 
sodium metasilicate at 13.42 and forming the PVA and colloidal silica dispersion, the 
encapsulation efficiency increased to 1.2% (Experiment 5). 
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As a result, formulations from experiments 4 and 5 were carried out and were compared here 
on. Although it can be argued that these encapsulation are low, the actual concentration of 
OSA measured from the microspheres were, 5µg/ml from the microspheres with sodium 
metasilicate at pH 7 and 12.77µg/ml from microspheres containing sodium metasilicate at pH 
13.42. These concentrations are ideal for cell viability as described in the previous chapter. 
Indeed, at high concentration, OSA can lead to cell apoptosis (Shie et al. 2011). It is therefore 
important that the concentration of orthosilicic acid released from the microspheres is of a 
therapeutic concentration leading to a positive biological effect. 
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4.3.1.2 Morphology and size  
Scanning electron microscopy (SEM) images showed the morphology and micro-structure of 
the PLGA microspheres produced with the different pH of sodium metasilicate.  
 
Figure 4.4: SEM images of PLGA microspheres produced without sodium metasilicate (A 
and D), with sodium metasilicate at pH 7 (B and E) and sodium metasilicate at pH 13 (C 
and F) 
As shown in Figure 4.4, the microspheres produced with sodium metasilicate at pH 7 were 
larger in size and looked to be more porous than the microspheres produced with sodium 
metasilicate at pH 13.42, which showed to have a more close knit structure similar to that of 
the control. The particles were of disc shape morphology, rather than complete spheres. This 
could be attributed to the stirring speed while forming the microspheres. It has previously 
been suggested that the stirring speed determines the size and shape of the microspheres 
(Song et al. 2006).    
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Figure 4.5: Particle size distribution curves for PLGA microspheres without sodium 
metasilicate, with sodium metasilicate and pH 7 and pH 13. 
The particle size distribution is displayed as a Gaussian function which defines the normal 
distribution of a certain population. In this case the median diameter for each formulation was 
determined: indicating that half the microspheres lie below 50% (D50). Similarly 90% of the 
microspheres lie below the D90 and 10% lie below the D10 (Figure 4.5).  
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Table 4.3: The D10, D50 and D90 values of PLGA micro-particles, from which the particle size 
distribution span is calculated.   
 
The D50 (50%) for the microspheres formed with sodium metasilicate at pH 7 was 420µm and 
302 m for pH 13.42. These results were in accordance with the observations from the SEM 
images (Figure 4.4). The microspheres containing no sodium metasilicate were smaller in size 
when compared to the microspheres produced with sodium metasilicate. There was no 
significant difference, however, in the particle size distribution when microspheres were 
produced with varying pH of sodium metasilicate (Table 4.3), these results are in accordance 
with the observations from the SEM images. Indicating that sodium metasilicate at pH 7 and 
pH 13 does not change the size of the microspheres; instead the changes in pH alter the 
surface topography of the microspheres, seen in Figure 4.4. 
 
 
 
D10 D50 D90 
Span                
(D90-D10/D50) 
Control 35µm 232µm 472µm 1.88 
pH 6.87 255µm 420µm 689µm 1.03 
pH 13.4 137µm 301µm 580µm 1.47 
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4.3.1.3 In vitro release of sodium metasilicate from PLGA microspheres 
In vitro release studies were carried out to determine the release of sodium metasilicate, in the 
form of orthosilicic acid from the PLGA microspheres. It is important to tailor the release of 
orthosilicic acid from silicon containing biomaterials in order to have a positive biological 
effect in bone repair, rather than a toxic effect. The amount of OSA encapsulated into the 
PLGA microspheres was determined by dissolving them in DCM and measuring the OSA 
released from the polymeric matrix. Release of OSA was determined over time and the 
concentration determined using the colourimetric assay is described in section 4.2.6. The 
results are summarised in Table 4.4 
Table 4.4: Actual amount of OSA entrapped in microspheres, concentration of OSA from 
microspheres after 600H and cumulative % release determined. 
 
The release of OSA from PLGA microspheres prepared with sodium metasilicate at pH 13 
and pH 7 was determined. The actual amount of OSA determined after dissolving the PLGA 
microspheres was 12.78µg/ml, when prepared with sodium metasilicate at pH 13. The release 
 Sodium metasilicate at pH 
13 
Sodium metasilicate at pH 
7 
Actual concentration of 
OSA entrapped in 
microspheres (µg/ml) 
12.78 6.95 
Concentration of OSA 
released after 600h 
(µg/ml) 
9.82 6.75 
% release of OSA after 
600h (%) 
77 97 
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of OSA from the microspheres after 600h was 9.82µg/ml, that is, approximately 77% of the 
OSA was therefore released from the microspheres after 600h (Table 4.4).  
Microspheres prepared with sodium metasilicate at pH 7 had a lower encapsulation efficiency 
compared with microspheres prepared with sodium metasilicate at pH 13. The actual 
concentration of sodium metasilicate entrapped within the microspheres was 6.95µg/ml. After 
600h, approximately 97% of OSA was released from within the PLGA microspheres (Table 
4.4).    
 
Figure 4.6: Release of orthosilicic acid (µg/ml) from PLGA microspheres loaded with sodium 
metasilicate at pH 7 and 13. Each point represents the average of 3 tests.  Error bars 
indicate the standard deviation of the mean. 
0.0
2.0
4.0
6.0
8.0
10.0
12.0
0 100 200 300 400 500 600 700
C
u
m
u
la
ti
ve
 C
o
n
ce
n
tr
at
io
n
 o
f 
O
SA
 (
µ
g/
m
l)
 
Time (H) 
Control
Sodium
metasilicate
pH 7
Sodium
metasilicate
pH 13
Chapter 4 
119 
 
Dissolution studies were carried out to observe the release of orthosilicic acid, in vitro. The 
release was carried out over a period of 25 days and the cumulative concentration was 
determined (Figure 4.6).  
The release of orthosilicic acid from microspheres prepared with sodium metasilicate pH 7 
and pH 13 showed similar release profiles, which can be divided into a biphasic release, 
whereby initially a rapid release, was observed during the first 50h of the study. This initial 
burst of release can be attributed to the presence of sodium metasilicate either on the surface 
of the microspheres, or near the exterior surface of the polymer. The release of OSA from the 
PLGA matrix is released as a function of solubility as well as the penetration of water into the 
polymeric matrix. The second phase after 50h, demonstrates that OSA is released 
progressively as the PLGA polymer starts to degrade, as the dissolution medium starts to 
hydrolyse the polymer into soluble oligomeric and monomeric products. The degradation of 
the polymer therefore creates a passage for OSA to diffuse out of the polymer and into the 
dissolution medium.  The biphasic release profile in Figure 4.6 shows an initial zero-order 
release profile, whereby a constant rate of OSA is release independent of the initial OSA 
concentration in the microspheres (equation 4-6), this was then followed by a progressive 
release and after 50h a constant amount of OSA was observed.  
 
 
 
 
 
Qt = Q0 + K0t 
Q0 – initial amount of drug 
Qt – cumulative amount of drug released at time t 
K0 – zero order release constant 
t - time in hours  
 Equation 4-6 
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Figure 4.7: Cumulative (%) release of OSA from PLGA microspheres loaded with sodium 
metasilicate at pH 7 and 13 
The cumulative percentage release of OSA was compared from the two types of microspheres 
formed, that is, with sodium metasilicate at pH 7 and 13 (Figure 4.7). Microspheres prepared 
with sodium metasilicate at pH 7 released approximately 97% of the OSA, indicating that 
almost all the OSA entrapped within the microspheres was released after 600h in dissolution 
media (Figure 4.7). Microspheres prepared with pH 13, however, released approximately 76% 
of the OSA entrapped during the same time period. This difference in % release can be 
attributed to the morphology of the microspheres. The microspheres prepared with sodium 
metasilicate at pH 13, were less porous and had a more intricate network compared to those 
prepared with sodium metasilicate at pH 7. The decrease in number of pores reduced the 
diffusion rate of OSA, therefore slowing the release of OSA. It is also known that basic drugs 
such as sodium metasilicate at pH 13, may react with the terminal carboxyl group of PLGA 
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creating strong ionic interactions between the polymer and OSA, thus resulting in an 
incomplete release of OSA. OSA was easily diffused, however, from the micro-particles 
prepared with pH 7 sodium metasilicate due to an increased number of pores, as well as, a 
faster rate of erosion of the polymer.  
4.3.2 Synthesis of β-dicalcium silicate and PLGA microspheres 
Calcium silicate / PLGA (CS/PLGA) composites were fabricated as microspheres, by 
encapsulating calcium silicate into PLGA using the s/o/w emulsion technique (Section 
4.2.4.2.), to further investigate the in vitro release of OSA. Initially calcium silicate was 
characterised using XRF and XRD analysis. The effect of cell survival was observed on the 
CS only composites before its encapsulation into the polymer PLGA. Various amounts of CS 
were encapsulated into the PLGA microspheres and the encapsulation efficiency was 
calculated. Microspheres size and morphology were determined, followed by the release of 
OSA from the CS/PLGA composites.   
4.3.2.1 Characterisation of β-dicalcium silicate 
X-ray diffraction patterns of β-dicalcium silicate synthesised using the Pechini method, 
showed the phase purity of sintered calcium silicate (Figure 4.8), without the production of 
lime and other unreacted materials. Sharp peaks indicate pure β-dicalcium silicate powder. 
The results are in accordance with other published data (Tan et al. 2010).  
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Figure 4.8: XRD pattern of calcium silicate produced by the Pechini method; calcined at 
800oC for 3 hours. 
Elemental analysis using X-ray fluorescence (XRF) of β-dicalcium silicate showed sharp 
peaks representing the presence of calcium and silicon in the sintered powder (Figure 4.9).  
The amount of oxides and elements present in the calcined powder are shown in Table 4.5. 
The concentration of CaO and SiO2 are highest accounting to the total of 82.7% and 16.5% 
respectively. 
Chemical composition CaO SiO2 Element Ca Si 
Concentration (%) 82.72 16.5 Concentration 
(%) 
89.69 9.70 
 
Table 4.5: XRF analysis of oxides and elements present in β-calcium silicate powder 
   β-dicalcium silicate 
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Figure 4.9: X-ray fluorescence (XRF) peaks indicative of elemental calcium and silicon. 
4.3.2.2 Response of osteoblasts to CS composites 
Calcium silicate composites were made in disc shapes and MC-3T3 cells were seeded onto 
the samples. The response of these cells was evaluated using DAPI staining, whereby, cell 
attachment and cell proliferation was determined over a period of 7 days.   
It was important to determine the effect of calcium silicate on cell survival before 
incorporating it into the PLGA polymer. Figure 4.10 illustrates that initially MC-3T3 cells 
attached onto the surface of the composite at day 1, however cell attachment and proliferation 
decreased on the surface of the composite, during day 3, 5 and 7.   
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Figure 4.10: Response of MC-3T3 cell attachment and proliferation to calcium silicate 
cements. Scale bar denotes 200µm 
The decrease in cell attachment could be attributed to two factors; an increase in 
concentration of orthosilicic acid in the growth medium as well as the production of calcium 
hydroxide when CS become hydrated, leading to either a highly acidic or alkaline 
environment for the cells to survive. The release of OSA from the calcium silicate composites 
was determined, shown in Figure 4.11. 
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Figure 4.11:  Cumulative release of OSA from calcium silicate only composites. Error bars 
indicative of the standard deviation. Each point represents an average of 3 tests.  
The cumulative concentration of OSA released from the calcium silicate composites was 
approximately 2.9mg/ml after 600h release; the release of orthosilicic acid was of zero order 
kinetics, whereby the elimination of orthosilicic acid from the calcium silicate composites is 
independent of concentration of silicon in the composite for the 600h release. Once all the 
OSA is released from within the composite and the maximum concentration is released the 
graph should start to plateau. Therefore, this reaction is of zero-order kinetics for only a 
limited time.    
When comparing the release of OSA to osteoblast cell response to the composite, it was 
illustrated that cell attachment and proliferation decreased over the 7 day period. This was 
attributed to the high concentration of orthosilicic acid at these time points, that is, the 
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concentration of orthosilicic acid was approximately 1mg/ml at day 7 (Figure 4.11 (inset 
graph)). In the previous chapter it has been shown, that high concentrations of orthosilicic 
acid can have a toxic effect on cells, leading them to apoptose. The high concentrations of 
orthosilicic acid present in the PLGA/calcium silicate composite prevent cell attachment and 
proliferation.  
Calcium silicate was therefore encapsulated in the PLGA polymer, which acts a diffusion 
barrier for the release of OSA and hence creating a sustained release of orthosilicic acid at 
low concentrations.    
4.3.2.3 Synthesis and encapsulation efficiency of calcium silicate/PLGA 
composites 
The PLGA/CS microspheres were synthesised using the s/o/w evaporation technique, various 
amounts of calcium silicate was incorporated into the microspheres to obtain the maximum 
encapsulation efficiency. It was noted that the morphology of the microspheres depends on 
the amount of calcium silicate present as it was seen that excess calcium silicate, led to the 
production of damaged microspheres. Initial stirring speeds and polymer concentration were 
optimised during particle formation. It was seen that high stirring speeds and high 
concentrations of polymer, led to the agglomeration of the microspheres.  
Agglomerated PLGA/CS microspheres were formed when prepared with 200mg and 100mg 
of CS, (Figure 4.12, A and B). PLGA/CS microspheres formed with 50mg and 20mg of CS 
however, produced homogenous microspheres with little presence of excess calcium silicate 
on the exterior of the microspheres.  
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Figure 4.12: SEM images of damaged PLGA/CS microspheres prepared with excess amounts 
of calcium silicate, A – 200mg of CS, B – 100mg, C-50mg, D- 20mg. 
The encapsulation efficiencies were determined with the various amounts of CS added into 
the polymer, for microspheres production, after washing the microspheres with distilled 
water, this removed the excess calcium silicate present on the surface of the microspheres. 
The microspheres were then dissolved in DCM to degrade the polymer and release the 
calcium silicate into the water phase, the amount of OSA present was measured using the 
colourimetric assay (Section 4.2.6).  
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Table 4.6: Encapsulation efficiency of the amount of calcium silicate entrapped within the 
PLGA microspheres.  
 
Microspheres produced with 20 and 10mg of CS showed to have the highest encapsulation 
efficiency at 5.7% and 6.1% respectively. These microspheres were used here-on to determine 
the release of OSA from these PLGA/CS composites.   
4.3.2.4 Size and morphology of PLGA/CS microspheres 
The particle size distribution of the microspheres prepared with 10mg and 20mg of calcium 
silicate was determined. There was no significant difference in the size of the microspheres 
prepared with calcium silicate, whereby 50% of the microspheres were 106µm and 104µm for 
the microspheres prepared with 10mg and 20mg of CS (Table 4.7).  
 
 
 
 
 
Amount of CS (mg) Encapsulation Efficiency (%) Mass encapsulated (mg) 
200 1.21 2.42 
100 2.28 2.28 
50 2.34 1.17 
20 5.67 1.13 
10 6.07 0.607 
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Table 4.7: Size distribution of PLGA/CS composites. D10, D50 and D90 values of PLGA 
microspheres from which the particle size distribution span is calculated.   
Microspheres of each sample were measured 10 times and each coloured line represents one 
measurement, from Figure 4.13 it can be seen that the measurements and methods were 
reproducible. 
 
Figure 4.13: Size distribution pattern of microspheres produced with 10mg and 20mg of CS. 
Each sample was measured 10 times.   
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Figure 4.14: SEM images of PLGA/CS composites formulated with various amounts of CS. 
Excess calcium silicate can be seen on the surface of the microspheres produced with 20mg 
of calcium silicate. 
The morphology of the microspheres was examined using the SEM, the microspheres 
formulated without CS were more of a disc shape rather than spherical, this could be due to 
the formation of a vacuum formed inside the SEM equipment (Figure 4.14). Another factor 
attributing to this morphology could be the speed used when initially forming the 
microspheres. The microspheres produced with CS, however, showed to be spherical in 
shape, with some pores present on the surface. Excess calcium silicate was present on the 
surface of the PLGA/CS microspheres prepared with 20mg calcium silicate, when compared 
to those prepared with 10mg of calcium silicate.    
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4.3.2.5 In vitro release of OSA from PLGA/calcium silicate microspheres 
Dissolution studies were carried out on PLGA/CS microspheres whereby the release of OSA 
was determined over time.   
 
Figure 4.15: Cumulative release of OSA from PLGA/CS composites over time. Each point 
represents an average of 3 tests. Error bars represent the standard deviation of the mean. 
In vitro release of OSA from PLGA/CS microspheres was determined and is shown in Figure 
4.15. The release of OSA over the 552h was a linear, first order relationship between the 
loading and the release of calcium silicate. The initial amount of calcium silicate added into 
the emulsion for the production of microspheres, had no significant effect on the amount of 
OSA released at a given time, that is, approximately the same concentration of OSA was 
released from both the batches at any given time.  
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The PLGA coating decreased the amount of OSA released from the calcium silicate, when 
compared to the release of OSA from calcium silicate only (Figure 4.11). The release profile 
can be divided into stages, whereby the initial release of OSA is from the surface of the 
particles. The second phase is the diffusion of OSA from within the PLGA microsphere as it 
degrades over time. 
 
Figure 4.16: Cumulative (%) release of OSA from the PLGA/CS microspheres. Each point 
represents an average of 3 tests. Error bars indicate the standard deviation of the mean.  
The maximum OSA released from the microspheres after 552h was approximately 46% for 
the microspheres with 10mg of calcium silicate and 22% with those prepared with 20mg. 
There is a steady release of OSA from these PLGA/CS microspheres, from both batches, 
independent of the amounts of CS used in the formation of these particles (Figure 4.16).  
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The amount of OSA released at a given time is at a therapeutic dose for cell survival 
indicating that the PLGA coating surrounding calcium silicate modifies the release of OSA in 
vitro.  
4.4 Discussion 
The aim of this investigation was to assess PLGA as a delivery mechanism for orthosilicic 
acid, to be further applied in orthopaedic reconstruction. Sodium metasilicate or calcium 
silicate was entrapped into the polymeric matrix and the encapsulation efficiency and the rate 
of release of OSA was determined.  
Different formulations to incorporate silicon into the PLGA microspheres using the w/o/w 
emulsion-solvent evaporation method were investigated. Little or no OSA was detected when 
the microspheres were formed with PLGA and sodium metasilicate at pH 13.42, it has been 
suggested that silica acts as an emulsifier to PLGA particles, whereby silica particles reside 
exclusively on the interface between the PLGA oil droplet and PVA solution, and therefore 
very few silica particles are encapsulated into the sphere after solidification, this is often 
known as the Pickering effect (Li et al. 2011).   
Various pH conditions were investigated to increase the encapsulation of sodium metasilicate 
into the polymeric matrix. The pH of sodium metasilicate was changed from 13.42 to 7 and 
the diffusion of sodium metasilicate into PVA was reduced by saturating the large water (W2) 
phase with a Si source. By ‘ion-trapping’ the sodium metasilicate salt into the PLGA polymer, 
increased OSA encapsulation. Prior to any pH changes, the sodium metasilicate salt would 
easily diffuse from the PLGA into the PVA solution. OSA is hydrophilic, therefore diffuses 
out of the partition from the dispersed oil phase (PLGA) into the continuous phase (PVA), 
and therefore leads to poor encapsulation efficiency (Jain 2000).   
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Calcium silicate ceramics have shown to possess excellent bone regeneration ability, as they 
have shown to enhance the proliferation of osteoblasts and promote osteogenesis when 
compared to calcium phosphate cements alone.  Calcium silicate ceramics are also well 
tolerated in vivo. Recently there have been some studies in the literature focussing on the 
composites created by combining polymers and calcium silicate, in this case the polymer used 
is PLGA. The high ionic dissolution of calcium silicate, leads to a high local pH environment, 
which results in an adverse cellular response, and may not be suitable for tissue engineering 
applications. This limitation of calcium silicate can therefore be mitigated by developing 
CS/polymer composites (Zhao et al. 2011).  
Calcium silicate was encapsulated into PLGA micro-particles using the solid/oil/water 
emulsion technique. This solvent-evaporation technique is often used when a ‘drug’ such as 
calcium silicate cannot be dissolved in a carrier solvent. The s/o/w method requires a very low 
drug particle size in order to allow for a complete encapsulation of the drug crystals. Excess 
calcium silicate to polymer ratio that is 200mg and 100mg disrupted the formation of micro-
particles, however by reducing the amount of CS added into the polymer to 10 and 20mg, 
formed porous microspheres between 104-106µm in diameter. The encapsulation efficiency 
of calcium silicate was significantly higher, when compared to that of sodium metasilicate; 
the CS particles are entrapped in the polymeric matrix rather than adhering to the surface of 
PLGA microspheres like the silicate salt.  
The key advantage of forming microspheres is that they have the potential to accommodate 
high ‘drug’ loadings and are able to supply continuous and sustained dosages. Micron size or 
less, delivery particles can often be injected at a targeted site of a patient, where it will have a 
localised effect and therefore increases patient compliance, the polymeric matrix also protects 
the bioactive agent in vivo. Therefore the slow release of orthosilicic acid from the PLGA 
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microspheres plays an important in the nucleation and growth of apatite, and influence the 
biological metabolism of osteoblastic cells, which are essential to the mineralisation process 
and bone bonding mechanism (Wei et al. 2008). 
The release of OSA from microspheres prepared with sodium metasilicate is divided into a 
biphasic release. The initial rapid release is attributed to the silicate salt attached either to the 
surface of the micro-particles or nearby the exterior surface of the polymer. Metasilicate 
migrated towards the external aqueous phase of the micro-particles, due to its hydrophilic 
nature and therefore precipitates on the outer surface of the particles, leading to the initial 
burst of OSA.  
The remaining OSA from within the polymeric matrix is released in the second phase of the 
release profile, whereby OSA is dissolved and transported out of the microspheres (Xue & 
Shi 2004). The release can also be due to the degradation of the PLGA polymer, which 
creates channels allowing the passage of the entrapped OSA.   
Various studies have shown that by incorporating calcium silicate into polymers not only 
induces bioactivity into the composite but also improves the composites mechanical 
properties and hydrophillicity. The PLGA/CS microspheres were formed because of the 
Pickering effect, whereby the PLGA solution acts as a ‘glue’ and calcium silicate acts as the 
stabiliser for the microspheres (Li et al. 2011). The release of Ca and Si ionic products 
neutralises the acidic by-products from degrading PLGA microspheres and therefore stabilises 
the pH value of the surrounding environment.  
Release profiles for 10mg and 20mg CS loaded calcium silicate microspheres follow the 
similar release profiles as the microspheres entrapped with sodium metasilicate. The initial 
rapid burst of OSA due the presence of excess calcium silicate on the surface of the PLGA 
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microspheres, followed by a progressive release rate for 4h and then a gradual increase as 
PLGA degrades and subsequent diffusion takes place. Approximately 4.4µg/ml OSA was 
released over the time period of 552 h, the sustained release can be beneficial for the 
mineralisation of bone in vivo.  
Orthosilicic acid was also encapsulated within alginate, a commonly used hydrogel for tissue 
regeneration; little or no release of OSA was observed from the hydrogel beads. This was 
further investigated and the results are described in chapter 5, whereby it was observed that 
OSA has a significant effect on the degradation of alginate.     
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4.5 Conclusion 
Various researchers have developed silicon containing biomaterials and have investigated 
apatite formation, cell attachment and proliferation, very few however, have observed the ions 
released from these ‘bone graft substitutes’ and evaluated the therapeutic levels needed to 
have a positive biological effect.  
A delivery system for the tailored release of orthosilicic acid for bone mineralisation was 
developed, whereby, sodium metasilicate and calcium silicate were entrapped into PLGA 
microspheres and the release of OSA was determined.  Due to the novel nature of sodium 
metasilicate/PLGA formulations, there are a very few similar studies to compare the OSA 
release profiles to. The presence of sodium metasilicate increased the porosity of PLGA 
microspheres, and released therapeutic levels of OSA suitable for in vitro cell survival. 
Calcium silicate ceramics were coated with PLGA to modify the release properties of the 
ceramic. PLGA coating acts as a barrier to CS and the release of OSA is decreased 
significantly, when compared to the release of CS on its own.  In addition the alkaline 
degradation products of CS are neutralised by the acidic degradation products of PLGA, 
making it a favourable environment for cell viability. 
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5. Modification of alginate degradation properties using 
orthosilicic acid 
5.1 Introduction 
There is a significant and growing need for the development of materials that can be used in 
the replacement and regeneration of human tissues (Kamitakahara et al. 2008) At present, the 
`gold standard' in the regeneration of most tissues require harvesting from the patient's own 
tissue (autogenic) (Heinemann et al. 2009) Although a range of synthetic materials has been 
used for tissue regeneration, relatively few have replaced autograft tissues as the `gold 
standard'.  A current area of significant interest is the repair of tissues through the delivery of 
cells to a specific site in the body (Hunt & Grover 2010).  The therapeutic delivery of such 
cell populations has been proposed to assist in the treatment of autoimmune disorders such as 
rheumatoid arthritis (Jorgensen et al. 2004) and is also thought to have potential to facilitate 
the regeneration of connective tissues such as cartilage and bone (Tuan et al. 2003).  As a 
consequence of this, there has been a significant drive towards the development of hydrogels 
as cell delivery vehicles, since they consist largely of water, enabling good mass transport, 
and have been proposed to resemble the extracellular matrix (Bhattarai et al. 2006).  In this 
chapter we show that the degradation of an alginate hydrogel can be tailored through the 
addition of orthosilicic acid. 
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5.1.1 Biodegradable polymer – Alginate 
Alginate is a polysaccharide derived from marine brown algae (Tønnesen & Karlsen 2002), 
and has been widely used in tissue engineering, wound healing as well as a food additive. 
Alginate is composed of (1-4) linked β-D-mannuronic acid (M unit) and α-L-guluronic acid 
(G unit). Alginate hydrocolloid gels ionotropically when combined with divalent cations such 
as calcium. Gelation of the alginate solution occurs between the G - blocks of adjacent 
alginate chains, creating ionic interchange bridges (Rowley et al. 1999), also known as egg 
box junctions.  
 
 
Figure 5.1: Molecular structure and monomer units of alginate; (Jovanovic et al 2012) 
While significant progress has been made towards the use of alginate in a clinical context, one 
major barrier remains the unpredictable degradation rate and often precipitous drop in 
mechanical properties when maintained in culture conditions or placed in vivo. It has been 
suggested that this decrease in mechanical properties is usually due to an outward flux of 
crosslinking ions into the surrounding medium.   
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A range of modifications have been made to alginate hydrogels to enhance biological function 
or adjust mechanical properties (Augst et al. 2006), however, relatively little research has 
been carried out on the control of degradation.     
Bioactive molecules are often incorporated with growth factors that can be released from the 
material to enhance the repair of the tissue specified (Silva et al. 2007) However, trace 
elements such as silicon have recently become of great interest in regenerative medicine. 
Silicon has a number of advantages when compared to traditional growth factors, for example 
it does not induce an adverse immunogenic response and is known to enhance bone formation 
via both acellular and cellular mechanisms 
While authors have previously reported the reinforcement of alginate hydrogels by using 
silica particles (Coradin 2003; Sakai 2002),  there has been little investigation into the 
incorporation of the soluble form of silicon (orthosilicic acid) into the hydrogel. In this 
chapter the influence of OSA addition on the degradation and mechanical properties of an 
alginate hydrogel was evaluated by determining the silicate and calcium release from the gel 
in the presence of a potent calcium chelator (ethylenediamine tetra-acetic acid; EDTA) and a 
mechanism for the modification alginate hydrogel properties by interactions between the 
OSA, calcium and alginate is proposed. 
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5.2 Materials and methods 
5.2.1 Alginate hydrogel preparation 
All chemicals and reagents were purchased from Sigma-Aldrich (Gillingham, UK), unless 
stated otherwise.  Alginate hydrocolloid solutions of 2% w/w concentration were made by 
dissolving sodium alginate (20-40 centipoise (cps) for 2% w/v, Cat. No. 180947, Lot. 
08620BJ, MW 102,000-209,000, M:G ratio 1.56) in double distilled water on a heated stirrer 
plate  at 100
o
C.  
Non-modified alginate gels were prepared by the drop-wise method, whereby, the alginate 
hydrocolloid was added drop-wise using a 10ml plastic syringe into a 100mM calcium 
chloride, CaCl2, solution, stirred using a magnetic stirrer. The dispersion was allowed to stir 
overnight, until the beads were fully gelled. For beads that were modified with OSA, 25µg/ml 
Ammonium hexafluorosilicate (Fisher Scientific) was added to 10mL of the alginate 
hydrocolloid solution and mixed thoroughly, and the beads were formed as described 
previously. 
5.2.2 Alginate hydrogel bead degradation 
The degradation of modified and unmodified beads was determined by suspending the beads 
in 30mM EDTA solution, and the mean change in diameter was determined with time. The 
beads were removed from EDTA solution at different time intervals and images of the beads 
were taken using a digital camera attached to an optical microscope (Carl Zeiss, Welwyn 
Garden City, UK) at a magnification of 40X. Subsequently the diameter of the beads was 
determined using ImageJ (National Institute of Health, Maryland, USA). 
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5.2.3 Calcium release from alginate hydrogel beads 
The release of calcium from gelled beads was determined colourmetrically by measuring the 
intensity of a calcium sensitive dye Arsenezo III (AIII), which undergoes a colour change 
upon binding with calcium ions. 30µl of sample was taken every 30 minutes for 2 hours and 
analysed using 4ml of AIII solution, made up with, 400 µM AIII, 300µM NaCl and 200mM 
HEPES. Followed by the addition of 30µl of 20% (v/v) Triton X – 200 solution. The sample 
was mixed thoroughly and measured using a UV spectrophotometer at 656nm (Smith et al. 
2007). 
5.2.4 Orthosilicic acid release from alginate hydrogel beads 
To determine the release of OSA from alginate hydrogel beads, a known mass of beads was 
suspended in 300ml of Dulbecco’s Modified Eagle’s Medium (DMEM) which was placed in 
a shaker (Gallenkamp, UK) at 100rpm at 37
0
C. 4ml of DMEM was taken from the vessel at 
specified time intervals and passed through a 0.22µM filter.  To maintain a constant volume 
of the dissolution medium, 4ml of fresh DMEM was replaced after each measurement. 
5.2.4.1 Molybdenum blue method – colourimetric assay for OSA detection 
The reagents required for the colourimetric assay have been previous described in section 
4.2.5. Briefly, to quantify the release of OSA from the alginate hydrogels using the 
molybedenum blue colourimetric assay, includes 60 µl of 1M hydrochloric acid (HCl), 120µl 
of ammonium molybdate reagent, 90µl of Oxalic acid and 120µL of the reducing agent 1-
amino-2-napthol-4-suphonic acid (Kortesuo et al. 2000). The absorbance of the solution was 
determined at 650nm using a UV spectrophotometer (Cecil Instruments, UK). 
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5.2.5 Rheology  
Rheology derived from the Greek phrase panta rei meaning ‘everything flows’, is the study of 
deformation and flow of matter, whereby, the relationship between stress and strain within a 
material can be determined as a function of time, temperature etc.  The force per unit area 
acting on a sample is called stress, measured in Pascals (Pa), this result in the deformation of 
the sample called strain. Materials can be classified either as solids or liquids depending on 
their mechanical properties; however materials such as gels are referred to as viscoelastic 
materials as they have some elastic behaviour (solid) and some viscous behaviour (liquid). 
Oscillatory shear is used in the characterisation of viscoelastic materials such as biopolymers. 
In this method, both the stress and strain vary cyclically with time, with sinusoidal variation 
being the most commonly used. Based on the strain imposed and the stress response, material 
functions are defined to quantify the material behaviour. G´ the storage modulus and G´´ the 
loss modulus are defined as stress and strain amplitudes. Storage modulus is based on the 
amplitude of in-phase stress and loss modulus is based on the out-of-phase stress (Picout & 
Ross-Murphy 2003). 
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5.2.5.1 Monitoring alginate hydrogel mechanical properties using small 
deformation oscillatory rheology 
The influence of modification with OSA on the mechanical properties of alginate was 
determined using small deformation oscillatory rheometry on alginate hydrogel discs. To 
form the discs, 10ml of alginate 2% (w/w) hydrocolloid, with or without 25µg/ml ammonium 
hexafluorosilicate was poured into dialysis tubing and then placed into a 100mM CaCl2 to gel 
via external gelation overnight. The gelled alginate was then cut into 2mm thick discs and 
placed into un-supplemented DMEM and allowed to age for up to 14 days prior to 
measurement using a rheometer. All measurements were formed at 37
o
C using a stress 
controlled rheometer (TA Instruments, USA). The gels were characterised using 20mm 
stainless steel parallel plate geometry (sand blasted to prevent slippage) at 0.5% strain, across 
a frequency ω range of 0.1-100 rad/s. For the determination of G', measurements were carried 
out at 6.283 rad/s.  
5.2.6 Determining the structure of alginate hydrogels  
To determine the internal structure of the alginate hydrogels scanning electron microscopy 
(SEM) was carried out on non-modified and modified hydrogels. The samples were mounted 
onto a stub and etched at -90
o
C, to reduce ice crystal formation and were coated with gold 
(EMSCOPE, UK) before being viewed using the SEM (Philips XL30 ESEM FEG, 
Netherlands). 
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5.3 Results 
5.3.1 Determining alginate hydrogel degradation 
Modification of the calcium alginate hydrogel using the source of OSA made no visual 
difference to the hydrogel, which remained transparent with the formation of no mineral 
particulate within the gel matrix. A visual representation of the reduction in diameter of the 
unmodified and modified beads is shown in Figure 5.2. 
Figure 5.2: Degradation of calcium alginate beads in the presence of EDTA with and 
without orthosilicic acid addition. 
From Figure 5.3 it was seen that on immersion in EDTA, a potent calcium chelator, which 
breaks the cross-links between the calcium and the alginate, the non-modified hydrogel beads 
reduced in diameter so that after a period of 150 min of ageing the gel had entirely dispersed 
within the ageing medium. In the case of the OSA modified gel, the beads lost mass, but at a 
far slower rate than the control material.  After a period of 150 min of ageing in EDTA, the 
gel beads had only reduced in diameter by 45% (Figure 5.3).  
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Following further immersion in EDTA, there was no further reduction in average bead 
diameter and to completely disperse the gel it was necessary to mechanically disrupt the 
material by sonication followed by further immersion in EDTA.  
 
Figure 5.3: Calcium alginate beads were suspended in EDTA and the effect of OSA on the 
degradation of alginate beads was determined. Each point represents an average of 20 
measurements and error bars are indicative of the standard deviations.  
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5.3.2 Determining calcium release from alginate hydrogels 
Since the gel was produced by the formation of cross-links between the calcium ions and the 
guluronate residues of the alginate polymer and no other cross-linking ions were present, the 
release of calcium from the modified and non-modified alginate hydrogels was determined.  
From Figure 5.4 it can be seen that in the case of the non-modified alginate beads, there was 
an increase in the calcium content of the ageing media up to 120 min when calcium was 
detectable at a concentration of 60 mM. In comparison, there was little calcium released over 
a period of 120 min when the hydrogel had been modified using the source of OSA, with only 
10 mM detectable in 120 min of ageing (Figure 5.4). 
 
Figure 5.4: Calcium concentration measured when alginate beads were suspended in EDTA. 
Each point represents the overall mean from 3 experiments and the error bars are 
indicative of the standard deviation. 
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5.3.3 Determining the release of OSA from alginate hydrogels 
To determine whether OSA was released from the gel on ageing, silicate release from the gels 
was assayed.  Despite a 45% reduction in gel diameter, there was very little OSA released 
from the alginate hydrogel modified with OSA over 168 minutes (Figure 5.5).  Indeed the 
background concentration of silicate was comparable when there was no OSA loaded into the 
hydrogel beads.   
 
Figure 5.5: The concentration of OSA released from calcium alginate beads, determined 
using the molybdenum blue assay for orthosilicic acid detection. The error bars represent 
the standard deviation. 
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To determine whether the calcium ions were required for the interaction between the OSA 
and the alginate, alginate hydrocolloid was combined with a solution containing 1mg/ml 
OSA.  The dispersion was left to stand for 1 h and was then centrifuged.  The silicate content 
of the supernatant was shown to be 0mg/ml suggesting that the silicate was immobilised 
within the hydrocolloid, which was a pale yellow colour, indicating that OSA was present 
within the hydrocolloid (Figure 5.6).   
 
Figure 5.6: The affinity of alginate and OSA was tested with the ammonium molybdate 
assay. 
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5.3.4 Determining the microstructure of alginate hydrogels 
To further determine the calcium and OSA cross-link network, SEM images of the micro-
structure of the OSA modified beads were collected. From figure 5.7 it can be noted that the 
OSA modified gel has a much smaller and intricate network when compared to the network of 
the non-modified hydrogel, indicating that although OSA on its own does not gel alginate, in 
the presence of calcium ions, they form a finer microstructure. 
 
Figure 5.7: SEM images of showing the microstructure of non-modified (A) and modified (B) 
cross–linked alginate hydrogels.  
5.3.5 Determining the mechanical properties of alginate hydrogels 
The influence of the OSA on the mechanical properties exhibited by the gel was determined 
using small deformation oscillatory rheometry.  Prior to immersion in DMEM, there was no 
significant difference between the G' exhibited by the control and the OSA modified alginate 
hydrogels.  In the case of the unmodified alginate, there was a reduction in the G' of the gel 
over the period of the study from 9000 to 2200 Pa over a period of 14 days of ageing in 
DMEM (Figure 5.8).  This finding is in accordance with that reported by others (Hunt et al. 
2010).  In comparison, there was relatively little reduction in the G' exhibited by the OSA 
modified alginate, which was 12000 Pa at both days 0 and 12. 
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Figure 5.8: Mechanical stiffness, G´ (Pa) of modified and non-modified alginate hydrogels. 
Anova-two factor with replication was carried out and the p-value calculated at 0.019. 
5.4 Discussion 
Alginate hydrogels have been used in a variety of medical applications.  This is in part 
because they are tolerated well when placed in contact with the body, but also because they 
have a similar structure to glycosaminoglycans (GAGs), one important constituent of the 
extracellular matrix (Bhattarai et al. 2006).  As a consequence, alginates have been used for 
the encapsulation of cells such as chondrocytes, fibroblasts and mesenchymal stem cells for 
the regeneration of cartilage, skin and bone respectively.  One major drawback associated 
with the use of alginate in the body is that it has a rapid and often unpredictable degradation 
profile (Hunt et al. 2010).  In this study, it has been shown that the degradation of an alginate 
hydrogel can be retarded by the addition of OSA and that this modification also maintains the 
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mechanical integrity of the gel when immersed in culture medium.  While several authors 
have previously reported the reinforcement of alginate hydrogel using silicate particles 
(Coradin et al. 2003; Sakai 2002) to date no-one has evaluated the influence of soluble silicate 
species on gel properties.  
Gelling of alginate occurs as a result of the formation of ionic cross-links between carboxyl 
groups in guluronic acid residues within the polysacharride.  The collection of carboxylic acid 
groups within the guluronate residue are termed the egg-box junction.  Each calcium ion is 
then chelated by two alginate molecules, forming cross-links, thus resulting in gelation of the 
hydrocolloid.  When immersed in double distilled water alginate will maintain its mechanical 
properties, however, in the presence of monovalent ions (K
+
 or Na
+
) ion exchange will occur 
with the cross-linking Ca
2+
 resulting in a rapid reduction in mechanical properties.  Indeed, 
we have previously reported almost complete degradation within one week of ageing in 
culture medium.   Given the varying ionic concentrations found at different sites in the body 
and even in different culture media, the degradation properties of the resulting gel can be 
unpredictable and this remains a major obstacle for the use of alginate hydrogels in medicine.   
The addition of OSA to the hydrocolloid enhanced the stability of the hydrogel, and the 
systematic investigation suggests that this is most likely achieved by each OSA molecule 
forming an interaction with one or more calcium ions, which prevents them being lost from 
the structure - even in the presence of the potent calcium chelator EDTA.  There have been 
numerous mentions of the interaction of silica with calcium and alginate in the literature and 
despite the obvious ionic interactions between OSA and calcium ions in solution, it has been 
reported that calcium ions can also be adhered onto the surface of OSA through one SiOH 
group (Perry & Keeling-Tucker 1998) indicating the presence of weak interactions between 
both of these components. Furthermore, it has been demonstrated that the OSA interacts with 
Chapter 5 
153 
 
the alginate hydrocolloid (Figure 5.6) and it has previously been reported that silicate species 
can form strong covalent interactions with alginic acid (Schwarz 1973) or hydrogen bonds 
between the silanol group and the alginate polymer (Avnir et al. 2006) OSA is negatively 
charged and so cannot form an association with the egg box junction in the absence of 
calcium, meaning that it cannot cause cross-linking and therefore gel formation. It is likely 
therefore, that in the absence of calcium, the OSA interacts via hydrogen bonding on the 
hydroxyl groups of both the guluronate and mannuronate residues of the alginate. The lack of 
calcium release in EDTA in the presence of OSA, however, suggests that the OSA may 
interact with calcium ions that are bound within the egg-box junction.  Furthermore, since 
OSA can polymerise in the pH range of 5-7 (Iler 1955), it is possible that a silicate network 
could interact with multiple calcium ions, thus augmenting the cross-links between the 
alginate chains. Indeed, the formation of such complex calcium - silicate networks is the 
origin of the mechanical integrity of the majority of Portland cement materials.  Clearly, the 
affinity of the OSA and alginate for calcium is higher than the affinity of EDTA for calcium 
alone. This is illustrated in Figure 5.9, showing the OSA interacting with the mannuronate 
groups within the cross-linked alginate, and also due to no significant reduction in G' it can be 
suggested that OSA polymerises on the surface of the gelled hydrocolloid. The minimal 
release of calcium indicates the interactions between the calcium and OSA.  
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Figure 5.9: Schematic diagram to demonstrate how calcium ions bind to and cross-link the 
egg-box junctions on the guluronate residues in the alginate polymer enabling gel 
formation.  The addition of calcium chelator EDTA, withdraws the calcium destroying the 
cross-links and dispersing the gel to reform the alginate hydrocolloid. The addition of OSA 
to the gel strengthens the interactions between the calcium and alginate holding it in the 
egg box junction even during aging in EDTA or culture medium, where exchange with 
monovalent ions can result in extensive degradation. 
What is particularly interesting is that although the gel that is formed with OSA reduces in 
diameter by 45% on immersion in EDTA (Figure 5.3) before plateauing, there is little 
measurable release of calcium or OSA from the alginate gel into the ageing medium (Figures 
5.4 and 5.5).  This suggests that the OSA and Ca
2+
 bound in the outer regions of the gel 
absorbed into the surface of the remaining mass of the bead following material degradation.  
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This would result in more extensive cross-linking of the remaining gel and may explain why 
despite there being a reduction in the diameter of the specimens, there was no measurable 
reduction in the G' of the material over the duration of the study.  By maintaining storage 
modulus and slowing degradation upon immersion in biological fluids, the modification of 
alginate using OSA may circumvent some of the problems associated with the application of 
alginate in cell delivery.  This is particularly important since cell phenotype is well known to 
be sensitive to local fluctuation in modulus and in order for cell delivery to be feasible the 
phenotypic stability of the delivered cells must be guaranteed to prevent potential teratoma 
formation. 
5.5 Conclusion 
In this chapter, it has been shown that the addition of OSA to alginate gelled with calcium 
ions can be used to retard hydrogel degradation, even in a potent calcium chelator (EDTA). It 
has been demonstrated that this adjusted degradation profile could be attributed to an 
interaction between the OSA, the hydrocolloid and the cross-linking agent calcium.  The 
ability to adjust the degradation of calcium alginate gels and to maintain mechanical 
properties even during degradation may help to widen the application of alginate in 
biomedical applications. 
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6. Conclusions and Future Works 
6.1 Overall Conclusion  
The role that silica plays in modifying bone structure was famously reported by Carlisle 
(1974) and Schwarz et al (1973). They demonstrated that when the levels of silica in an 
animal’s diet were decreased to a critical level, bone and cartilage deformation resulted.  
Many researchers used this finding as inspiration for the development of a generation of 
biomaterials, which incorporated silicon into their structure as a means to enhance bone 
formation.  Despite the plethora of biomaterials that now incorporate silicon, little is known, 
of the biological pathways involved in bone formation that may be influenced by silica.  
In this thesis, the role of silicon in early bone mineralisation was elucidated by investigating 
the dose response and in vitro mineralisation of osteoblasts exposed to various concentrations 
of orthosilicic acid. This led to the development of silicon release systems to provide a 
controlled dose of OSA. The effect of orthosilicic acid on the degradation properties of the 
hydrogel, alginate were also evaluated.  
In Chapter 3 the effect of orthosilicic acid was investigated on osteoblast responses in vitro. 
The optimum concentration of OSA was determined for cell survival and differentiation. It 
was noted that osteoblast survival was concentration dependent that is cell proliferation and 
differentiation increased when treated with of 5µg/ml OSA, however decreased in the 
presence of 20µg/ml of OSA. The presence of OSA in MC-3T3 cells, led to the early 
formation of phosphate and calcium nodules, indicating OSA may play a key role in early 
mineralisation of osteoblast cells. It is important to note, however, that the concentrations of 
silicon in the deposited mineral were so low as to be non-quantifiable.  
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RT-PCR analysis showed that OSA induced differentiation in rat bone marrow cells by up-
regulating early osteogenic markers such as ALP, osteocalcin, osteopontin and collagen type 
1. A significant effect on collagen type 1 expression was noted when cells were treated with 
OSA and further investigations were carried out to determine the direct interactions between 
collagen and silicon. OSA was also shown to have a distinct influence on collagen fibril 
formation, with certain concentrations of OSA producing a compact and irregular collagenous 
network, when compared with the control.  This confirms that OSA may indeed have a critical 
role in early matrix formation. 
Metal ions such as zinc, boron and strontium have also been shown to have a key role in a 
number of processes associated with bone formation. It has been reported that it is important 
to control the dosage if metal ions released from biomaterials whereby, the window between 
efficacy and toxicity is carefully maintained (Lakhkar et al. 2013).  
In Chapter 4, a delivery system for the tailored release of OSA for bone mineralisation was 
developed, whereby, sodium metasilicate and calcium silicate were entrapped into PLGA 
micro-particles and the release of OSA was determined. The presence of sodium metasilicate 
increased the porosity of PLGA microspheres when compared with the control, and released 
therapeutic levels of OSA suitable for in vitro cell survival. 
Calcium silicate ceramics were coated with PLGA to modify the release properties of the 
ceramic. The PLGA coating acts as a barrier to CS and the release of OSA was decreased 
significantly, when compared to the release of OSA from CS on its own.  In addition the 
alkaline degradation products of CS were neutralised by the acidic degradation products of 
PLGA, reducing the chance of polymer or ceramic degradation causing cytotoxicity in vivo. 
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OSA was also encapsulated in the hydrogel, alginate, however, little or no release of OSA 
was seen over time. This was further investigated in Chapter 5, where it was demonstrated 
that the structure of alginate was modified in the presence of OSA. It was shown that the 
addition of OSA to alginate gelled with calcium ions can be used to stop hydrogel 
degradation, even in a potent calcium chelator such as EDTA. It was demonstrated that this 
adjusted degradation profile could be attributed to an interaction between the OSA, the 
hydrocolloid and the cross-linking agent calcium.  The ability to adjust the degradation of 
calcium alginate gels and to maintain mechanical properties even during degradation may 
help to widen the application of alginate in biomedical applications. 
6.2 Future Work 
OSA was shown to up-regulate collagen type 1 expression as well as have a significant effect 
on collagen fibril formation and diameter. These changes in collagen fibrillogenesis suggest 
that silicon plays a fundamental role in the development of the extracellular matrix during 
formation. The next steps to further elucidate the biological pathway of silicon could be to 
investigate the formation of mineral within the collagen/OSA composite, in an acellular 
environment (Andre-Frei,1997). Mineral deposition in collagen/OSA composites can further 
be evaluated using XRD, FTIR and XRF to quantify changes in crystallite structure and 
composition.  Findings from this could suggest that silicon aids in the biomineralisation of 
collagen, which acts as a template for the deposition of calcium, phosphate and carbonate. 
TEM imaging would allow for the visualisation of the banding of collagen fibres, which 
would further enhance the underlying mechanism involved in the interaction between OSA 
and collagen fibre formation. Furthermore, the production of collagen from osteoblast cells 
treated with various concentrations of OSA could be assessed using various stains such as 
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Sirius Red. The effect of OSA on collagen contraction can also be determined by seeding 
cells either on the surface of the resulting gels or within the collagen gels.     
Designing a release system for the dissolution of OSA was also a key part of this 
investigation. Although PLGA has been shown to be a promising polymer for the delivery of 
non-toxic doses of OSA, various other polymers could be investigated to tailor the release of 
OSA from within the polymeric matrix. Other synthetic polymers include poly-ε-
carprolactone (PCL) as well as the copolymers of PLGA; poly-lactic acid (PLA) and poly-
glycolic acid (PGA), have been demonstrated to be potential polymers used in drug delivery 
technologies. With variable degradation rates and molecular weights as well as their ability to 
integrate well with osseous tissue, these polymers can further be investigated as release 
mechanisms for OSA as well as simultaneously acting as scaffolds for bone regeneration.   
PLGA microspheres, entrapped with sodium metasilicate and calcium silicate were fabricated 
using the water/oil/water and solid/oil/water emulsions, respectively. This method, although 
successful in forming homogenously sized microspheres, demonstrated a low encapsulation 
efficiency of OSA. Various other techniques, for example, using solvent casting methods 
could be employed to enhance the encapsulation efficiency and thus extend the delivery of 
OSA and making it a more efficient and implantable scaffold/drug delivery composite.  
Similar concentrations of OSA released from the PLGA microspheres, were used to evaluate 
cell mineralisation in vitro (Chapter 3), to further investigate the effect of PLGA/OSA 
microspheres in cellular conditions would be advantageous. Dose response curves can also be 
determined for rBMSCs before culturing the cells in trans-well plates and suspending the 
PLGA/OSA microspheres in the culture media, will allow for the release of OSA and the 
effect on cell differentiation and mineralisation will be determined. Together with evaluating 
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the effect of OSA on cell differentiation, the concentration of OSA released from the 
microspheres could be determined using inductively coupled plasma mass spectrometry (ICP-
MS) or atomic absorption spectroscopy (AAS) as it was noted that the ammonium molybdate 
colourimetric assay had limited usage in various medias, such as PBS and DMEM.  
The structure of alginate was modified in the presence of OSA and it has been shown that 
OSA interacts with the structure of the alginate polymer. Many hydrogels have a similar 
structure to glycosaminoglycan an important constituent of the extracellular matrix and thus 
used as a drug and cell delivery vesicles as well as wound dressings. One of the disadvantages 
of using hydrogels for these applications is that they have unpredictable degradation rates. 
Orthosilicic acid can therefore be incorporated into other hydrogels such as gellan, pectin, 
carrageenan and gelatin and their mechanical properties evaluated. 
By investigating the above will fully determine the role of orthosilicic acid in mineralisation 
and will provide a better understanding of the biological pathways involved in bone biology 
when orthosilicic acid is present. This will further allow in the synthesis of well-tailored 
silicon containing biomaterials that can be used clinically as bone replacements.    
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